From owner-diagnostics@net.bio.net Mon Jul 01 23:00:00 1996 Path: biosci!agate!spool.mu.edu!usenet.eel.ufl.edu!news-res.gsl.net!news.gsl.net!news.sprintlink.net!news-dc-5.sprintlink.net!news.sprintlink.net!news-dc-9.sprintlink.net!atmnet.net!newshub.cts.com!usenet From: b3748@cts.com (Bryan Kiehl) Newsgroups: bionet.general,bionet.cellbiol,bionet.cellbiol.cytonet,bionet.diagnostics,bionet.immunology,bionet.molbio.methds.reagnts,bionet.molbio.proteins,bionet.neuroscience Subject: Re: FDA TO REGULATE RESEARCH ANTIBODIES Date: Tue, 02 Jul 1996 04:55:11 GMT Organization: CTS Network Services Lines: 31 Message-ID: <4ra9n6$ivu@optional.cts.com> References: <31D7FA26.377@bioreagents.com> NNTP-Posting-Host: kiehl.cts.com X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.general:22598 bionet.cellbiol:5026 bionet.cellbiol.cytonet:586 bionet.diagnostics:948 bionet.immunology:9241 bionet.molbio.proteins:8233 bionet.neuroscience:14756 See bionet.diagnostics for discussion. James Stiehr wrote: >The FDA has just proposed new regulations on the sale and distributions >of antibodies and other reagents which will result in the withdrawal of >many research reagents from the US market. The net result of these >regulations is the reduction of tools available to the US research >community (non-US researchers will still have access to these tools). >The “Research Use Only” disclaimer WILL NOT prevent the FDA from removing >many reagents from the market if suppliers do not treat antibodies as In >Vitro Diagnostic Devices, submitting them to FDA for review, approval and >oversight. >For a more thorough review of the issue as well as the regulations >themselves, a special web page has been set up as an educational >resource. Visit http://www.earthnet.net/~affinity/fda for an overview of >the issues, the proposed regs, and what you can do about them. >Protect your access to these critically important research tools! Act >today! >James Stiehr >Affinity Bioreagents, Inc. Bryan Kiehl GenBio GenBio@msn.com San Diego, CA From owner-diagnostics@net.bio.net Mon Jul 01 23:00:00 1996 Path: biosci!rutgers!gatech!usenet.eel.ufl.edu!news-res.gsl.net!news.gsl.net!news.sprintlink.net!news-dc-5.sprintlink.net!news.sprintlink.net!news-dc-9.sprintlink.net!atmnet.net!newshub.cts.com!usenet From: b3748@cts.com (Bryan Kiehl) Newsgroups: bionet.general,bionet.cellbiol,bionet.cellbiol.cytonet,bionet.diagnostics,bionet.immunology,bionet.molbio.methds.reagnts,bionet.molbio.proteins,bionet.neuroscience Subject: Re: FDA TO REGULATE RESEARCH ANTIBODIES Date: Tue, 02 Jul 1996 04:53:08 GMT Organization: CTS Network Services Lines: 63 Message-ID: <4ra9jd$ivu@optional.cts.com> References: <31D7FA26.377@bioreagents.com> NNTP-Posting-Host: kiehl.cts.com X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.general:22599 bionet.cellbiol:5027 bionet.cellbiol.cytonet:587 bionet.diagnostics:949 bionet.immunology:9242 bionet.molbio.proteins:8234 bionet.neuroscience:14757 It is my understanding that the FDA does now require that reagents that may be used for diagnostic uses (e.g., cancer markers, infectious disease detection, etc.) are to be regulated. However, it also appears the amount of regulation is minimal. They require that the manufacturer follow good manufacturing practices. These include proper labeling and documentation during the manufacturing processes, as well as being able to field customer complaints and document how you deal with these. The regs also require that the company submit a notifcation with proposed labeling before marketing the product. This is then reviewed by the FDA for truth and accuracy. For example, is the reagent is an antibody, then one must identify what the antibody recognizes and be sure that all claims are accurate. If this is only a reagent and not a kit, there can be no performance claims. These reagents are intended for the user to establish the assay method. The user (e.g., pathologist, laboratory) must "validate" that the assay using this reagent performs well enough for diagnostic uses. The end user must also assure continued performance. If the manufacturer puts the reagent into kits or claims diagnostic performance, then he needs to provide data to the FDA. Otherwise, he mostly needs to just assure that the reagents are made well and packaged without error. For most smaller companies this may seem a burden at first, but similar regs are being established in Europe under ISO regs. Anyone else interpret this differently? To me, it doesn't look too bad. I also doubt that true research reagents that are never or rarely used in the clniical realm will ever be regulated. Remember, the FDA can only come down on a company that sells these reagents to groups that really do use them for human diagnostics. James Stiehr wrote: >The FDA has just proposed new regulations on the sale and distributions >of antibodies and other reagents which will result in the withdrawal of >many research reagents from the US market. The net result of these >regulations is the reduction of tools available to the US research >community (non-US researchers will still have access to these tools). >The “Research Use Only” disclaimer WILL NOT prevent the FDA from removing >many reagents from the market if suppliers do not treat antibodies as In >Vitro Diagnostic Devices, submitting them to FDA for review, approval and >oversight. >For a more thorough review of the issue as well as the regulations >themselves, a special web page has been set up as an educational >resource. Visit http://www.earthnet.net/~affinity/fda for an overview of >the issues, the proposed regs, and what you can do about them. >Protect your access to these critically important research tools! Act >today! >James Stiehr >Affinity Bioreagents, Inc. Bryan Kiehl GenBio GenBio@msn.com San Diego, CA From owner-diagnostics@net.bio.net Tue Jul 02 23:00:00 1996 Path: biosci!rutgers!uwm.edu!cs.utexas.edu!news.sprintlink.net!news-stk-200.sprintlink.net!news.sprintlink.net!news-stk-11.sprintlink.net!coopnews.coop.net!boulder.earthnet.net!usenet From: James Stiehr Newsgroups: bionet.general,bionet.cellbiol,bionet.cellbiol.cytonet,bionet.diagnostics,bionet.immunology,bionet.molbio.methds.reagnts,bionet.molbio.proteins,bionet.neuroscience Subject: Re: FDA TO REGULATE RESEARCH ANTIBODIES Date: Wed, 03 Jul 1996 08:38:29 -0700 Organization: Affinity BioReagents, Inc. Lines: 78 Message-ID: <31DA93F5.464B@bioreagents.com> References: <31D7FA26.377@bioreagents.com> <4ra9jd$ivu@optional.cts.com> NNTP-Posting-Host: slip1.earthnet.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 2.0 (Win16; I) Xref: biosci bionet.general:22615 bionet.cellbiol:5039 bionet.cellbiol.cytonet:593 bionet.diagnostics:950 bionet.immunology:9251 bionet.molbio.proteins:8244 bionet.neuroscience:14768 Bryan Kiehl wrote: > > It is my understanding that the FDA does now require that reagents > that may be used for diagnostic uses (e.g., cancer markers, infectious > disease detection, etc.) are to be regulated. > > However, it also appears the amount of regulation is minimal. They > require that the manufacturer follow good manufacturing practices. > These include proper labeling and documentation during the > manufacturing processes, as well as being able to field customer > complaints and document how you deal with these. The regs also require > that the company submit a notifcation with proposed labeling before > marketing the product. This is then reviewed by the FDA for truth and > accuracy. > > For example, is the reagent is an antibody, then one must identify > what the antibody recognizes and be sure that all claims are accurate. > If this is only a reagent and not a kit, there can be no performance > claims. These reagents are intended for the user to establish the > assay method. The user (e.g., pathologist, laboratory) must "validate" > that the assay using this reagent performs well enough for diagnostic > uses. The end user must also assure continued performance. > > If the manufacturer puts the reagent into kits or claims diagnostic > performance, then he needs to provide data to the FDA. Otherwise, he > mostly needs to just assure that the reagents are made well and > packaged without error. > > For most smaller companies this may seem a burden at first, but > similar regs are being established in Europe under ISO regs. Since many of the companies which provide reagetns are small companies, it becomes a major issue. Look in linscott's directory, you don't see many large companies with the deep pockets necessary to manage these regulations. GMP sounds nice and easy, but if you look at the actual requirements, they are not trivial. If people would like to see it, I would be happy to add it to the web site that has been created for this purpose: http://www.earthnet.net/~affinity/fda. > I also doubt that true research reagents that are never or rarely > used in the clniical realm will ever be regulated. Remember, the FDA > can only come down on a company that sells these reagents to groups > that really do use them for human diagnostics. It is unfortunate that a company cannot decide for itself that it does not want to be a diagnostic company and offer "dual use" products which can be identified as not appropriate for diagnostic use. There are federal consumer laws making it illegal to use a proguct contrary to its labeled use, however, pathologists (and other physicians) have managed to exempt themselves from these laws. Unfortunately, this leaves the supplier responsible for the use of its product. When you consider that most research reagents are sold to universities and ordered through the purchasing dept. to be delivered to "receiving" how can a company know who and how its product is used? What about the situation where today we sell a product that is not clinically relevant, but a paper comes out tomorrow saying it is? In that case, we have developed a market for a "true research reagent' that is discovered to have a new application. We still don't want to be a diagnostic company, yet at that point, according the the regs. we're selling an IVD and must therefore either conform to the regs and incur all of the marginal expenses for that single antibody (most of which only sell $5000-$10,000/year) or remove them from the market. Why can't we all be responsible suppliers and consumers (shades of Rodney King). If FDA, CLIA, suppliers and consumers could all agree to recognize that a product labeled "For In Vitro Experimental Use Only, Not for Diagnostic Use" really should not be used in any kind of clinical setting, then these would not need to be regulated by FDA. If CLIA found pathologists using them in their lab, sanctions could be applied. If FDA found suppliers promoting them for clinical use, appropriate disciplinary action could be taken. Honest companies who supply the research market with important research tools could go about their business either making quality products which their customers are happy with or going out of business if they are not - no harm done to anyone. James Stiehr Affinity Bioreagents, Inc. From owner-diagnostics@net.bio.net Tue Jul 02 23:00:00 1996 Path: biosci!rutgers!uwm.edu!vixen.cso.uiuc.edu!newsfeed.internetmci.com!swrinde!elroy.jpl.nasa.gov!usc!newshub.cts.com!usenet From: b3748@cts.com (Bryan Kiehl) Newsgroups: bionet.diagnostics Subject: Statistics/Graphic Package Date: Wed, 03 Jul 1996 23:13:00 GMT Organization: CTS Network Services Lines: 21 Message-ID: <4reuc2$b9u@optional.cts.com> NNTP-Posting-Host: kiehl.cts.com I am not associated with this company at all, but just want to note how useful this program has been. I am using Prisim by GraphPad to prepare FDA notifications and technical reports. For those interested in relatively simple programs that seem to integrate reasonable graphs and good statistics, you might want to take a look. With the complete version a little program called StatMate comes with it. This is a terrifec program, helping you predict sample size and testing power. For those with basic statistics and laboratory assay data, you almost can't go wrong. Info is at there Web page: http://www.graphpad.com And, really, I don't get anything for this. The company is in San Diego, but I've never been there and just like the program. And yes, I've looked at several. Bryan Kiehl GenBio GenBio@msn.com San Diego, CA From owner-diagnostics@net.bio.net Tue Jul 02 23:00:00 1996 Path: biosci!bcm.tmc.edu!pendragon!news.msfc.nasa.gov!elroy.jpl.nasa.gov!usc!newshub.cts.com!usenet From: b3748@cts.com (Bryan Kiehl) Newsgroups: bionet.general,bionet.cellbiol,bionet.cellbiol.cytonet,bionet.diagnostics,bionet.immunology,bionet.molbio.methds.reagnts,bionet.molbio.proteins,bionet.neuroscience Subject: Re: FDA TO REGULATE RESEARCH ANTIBODIES Date: Wed, 03 Jul 1996 23:09:01 GMT Organization: CTS Network Services Lines: 21 Message-ID: <4reu4j$b9u@optional.cts.com> References: <31D7FA26.377@bioreagents.com> <4ra9jd$ivu@optional.cts.com> <31DA93F5.464B@bioreagents.com> NNTP-Posting-Host: kiehl.cts.com Xref: biosci bionet.general:22621 bionet.cellbiol:5047 bionet.cellbiol.cytonet:594 bionet.diagnostics:951 bionet.immunology:9257 bionet.molbio.proteins:8248 bionet.neuroscience:14774 We are a small company too, but are in the diagnostics business and not the research business. I do understand the requirements to comply with GMP, but you might be surprised how this might not be so bad. I also wonder whether you will be in trouble with FDA if you receive a letter from the user that absolutely assures that the reagent you sell them will not be used for diagnostic purposes. Does this allow you to sell without FDA clearance? I'm not sure. If there are any FDA types that wish to comment, this might help some people. I also suggest that this may be an appropriate forum to disucss what GMP really does mean. There are alot of opinions, but the acutual practices may not be so terrible. Any comments? Bryan Kiehl GenBio GenBio@msn.com San Diego, CA From owner-diagnostics@net.bio.net Thu Jul 04 23:00:00 1996 Newsgroups: bionet.general,bionet.cellbiol,bionet.cellbiol.cytonet,bionet.diagnostics,bionet.immunology,bionet.molbio.methds.reagnts,bionet.molbio.proteins,bionet.neuroscience Path: biosci!bcm.tmc.edu!cs.utexas.edu!chi-news.cic.net!newsfeeder.sdsu.edu!newspump.sol.net!homer.alpha.net!uwm.edu!news.cse.psu.edu!rutgers!utcsri!utnut!wave.scar!usenet From: Any User <00useran@wave.scar.utoronto.ca> Subject: Re: FDA TO REGULATE RESEARCH ANTIBODIES X-Nntp-Posting-Host: pc208.scar3.utoronto.ca Content-Type: text/plain; charset=us-ascii Message-ID: Sender: usenet@wave.scar.utoronto.ca (news owner) Content-Transfer-Encoding: 7bit Organization: Scarborough College, U of T References: <31D7FA26.377@bioreagents.com> <4ra9jd$ivu@optional.cts.com> <31DA93F5.464B@bioreagents.com> Mime-Version: 1.0 Date: Fri, 5 Jul 1996 16:37:46 GMT X-Mailer: Mozilla 1.2N (Windows; I; 16bit) Lines: 83 Xref: biosci bionet.general:22648 bionet.cellbiol:5052 bionet.cellbiol.cytonet:596 bionet.diagnostics:953 bionet.immunology:9274 bionet.molbio.proteins:8268 bionet.neuroscience:14785 skejrjewlrlerlkjelrmlkel;resr serser eresrserserserserserserJames Stiehr wrote: >Bryan Kiehl wrote: >> >> It is my understanding that the FDA does now require that reagents >> that may be used for diagnostic uses (e.g., cancer markers, infectious >> disease detection, etc.) are to be regulated. >> >> However, it also appears the amount of regulation is minimal. They >> require that the manufacturer follow good manufacturing practices. >> These include proper labeling and documentation during the >> manufacturing processes, as well as being able to field customer >> complaints and document how you deal with these. The regs also require >> that the company submit a notifcation with proposed labeling before >> marketing the product. This is then reviewed by the FDA for truth and >> accuracy. >> >> For example, is the reagent is an antibody, then one must identify >> what the antibody recognizes and be sure that all claims are accurate. >> If this is only a reagent and not a kit, there can be no performance >> claims. These reagents are intended for the user to establish the >> assay method. The user (e.g., pathologist, laboratory) must "validate" >> that the assay using this reagent performs well enough for diagnostic >> uses. The end user must also assure continued performance. >> >> If the manufacturer puts the reagent into kits or claims diagnostic >> performance, then he needs to provide data to the FDA. Otherwise, he >> mostly needs to just assure that the reagents are made well and >> packaged without error. >> >> For most smaller companies this may seem a burden at first, but >> similar regs are being established in Europe under ISO regs. > >Since many of the companies which provide reagetns are small companies, >it becomes a major issue. Look in linscott's directory, you don't see >many large companies with the deep pockets necessary to manage these >regulations. GMP sounds nice and easy, but if you look at the actual >requirements, they are not trivial. If people would like to see it, I >would be happy to add it to the web site that has been created for this >purpose: http://www.earthnet.net/~affinity/fda. > >> I also doubt that true research reagents that are never or rarely >> used in the clniical realm will ever be regulated. Remember, the FDA >> can only come down on a company that sells these reagents to groups >> that really do use them for human diagnostics. > >It is unfortunate that a company cannot decide for itself that it does >not want to be a diagnostic company and offer "dual use" products which >can be identified as not appropriate for diagnostic use. There are >federal consumer laws making it illegal to use a proguct contrary to its >labeled use, however, pathologists (and other physicians) have managed to >exempt themselves from these laws. Unfortunately, this leaves the >supplier responsible for the use of its product. When you consider that >most research reagents are sold to universities and ordered through the >purchasing dept. to be delivered to "receiving" how can a company know >who and how its product is used? > >What about the situation where today we sell a product that is not >clinically relevant, but a paper comes out tomorrow saying it is? In >that case, we have developed a market for a "true research reagent' that >is discovered to have a new application. We still don't want to be a >diagnostic company, yet at that point, according the the regs. we're >selling an IVD and must therefore either conform to the regs and incur >all of the marginal expenses for that single antibody (most of which only >sell $5000-$10,000/year) or remove them from the market. > >Why can't we all be responsible suppliers and consumers (shades of Rodney >King). If FDA, CLIA, suppliers and consumers could all agree to >recognize that a product labeled "For In Vitro Experimental Use Only, Not >for Diagnostic Use" really should not be used in any kind of clinical >setting, then these would not need to be regulated by FDA. If CLIA found >pathologists using them in their lab, sanctions could be applied. If FDA >found suppliers promoting them for clinical use, appropriate disciplinary >action could be taken. Honest companies who supply the research market >with important research tools could go about their business either making >quality products which their customers are happy with or going out of >business if they are not - no harm done to anyone. > >James Stiehr >Affinity Bioreagents, Inc. From owner-diagnostics@net.bio.net Fri Jul 05 23:00:00 1996 Path: biosci!CS.Arizona.EDU!news.Arizona.EDU!hamblin.math.byu.edu!sol.ctr.columbia.edu!news.uoregon.edu!hunter.premier.net!newsfeed.internetmci.com!mr.net!news.mr.net!news From: Jeff Miner <"jminer@mr.net"@mr.net> Newsgroups: bionet.diagnostics,bionet.immunology Subject: New antisera Date: Tue, 02 Jul 1996 07:59:57 -0700 Organization: INCSTAR Corporation Lines: 10 Message-ID: <4rb6ra$dj0@news.mr.net> NNTP-Posting-Host: msp7-2.nas.mr.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 2.02 (Win16; U) Xref: biosci bionet.diagnostics:954 bionet.immunology:9276 INCSTAR Corporation now has available the following new histochemical antisera: 5HT2 receptor VAT bNOS 5HIAA Information on these and other histochemical antisera can be requested at http://www.incstar.com or call 1-800-328-1482 ext 726. From owner-diagnostics@net.bio.net Sat Jul 06 23:00:00 1996 Path: biosci!bcm.tmc.edu!pendragon!news.msfc.nasa.gov!newsfeed.internetmci.com!news.compuserve.com!news.production.compuserve.com!news From: Eric Masseus <100577.3707@CompuServe.COM> Newsgroups: bionet.diagnostics,bionet.diagnostics.prenatal,sci.med.immunology,sci.med.laboratory Subject: Ligase Chain Reaction Date: 7 Jul 1996 17:53:30 GMT Organization: Gooi-Noord Hospital, Dept Clin Chem, Netherlands Lines: 10 Message-ID: <4rotiq$3la$1@mhafn.production.compuserve.com> Xref: biosci bionet.diagnostics:955 bionet.diagnostics.prenatal:167 sci.med.immunology:6807 sci.med.laboratory:1671 The Monograph from Abbott Diagnostics Division about the ligase chain reaction can be found at http://ourworld.compuserve.com/homepages/Eric_Masseus_eforum keywords Ligase Chain Reaction Chlamydia trachomatis diagnostics analyzer immunoassay From owner-diagnostics@net.bio.net Mon Jul 08 23:00:00 1996 From: jjmacey@msn.com (john macey) Subject: Asia Biotech / Biomedical Manager Date: 9 Jul 96 15:19:44 -0700 Message-ID: <00005ae5+000001ec@msn.com> Path: biosci!rutgers!uwm.edu!cs.utexas.edu!swrinde!elroy.jpl.nasa.gov!news.msfc.nasa.gov!newsfeed.internetmci.com!ns1.netone.com!news.sprintlink.net!news-fw-12.sprintlink.net!news.msn.com!msn.com Newsgroups: bionet.diagnostics Organization: The Microsoft Network (msn.com) Lines: 125 I am presently searching for an operational management position in the life science field dealing in either the capital equipment or biotech / biomedical areas based in the Asia-Pacific region, preferably in either Singapore or Kuala Lumpur, Malaysia. In terms of career accomplishments I have the following to offer: · Progressive up-todate track record in the fields of immunology, toxicology, molecular biology, laboratory instrumentation and reagents and medical technologies. · Proven sales and marketing management success at some of the major players in the medical industry in positions of high visibility. · Ability to adapt to any international business development environment. · Extensive experience with capital equipment. More importantly I can bring the following career experiences: · Knowledge of the Asia market in terms of trends, channels of distribution and cultural differences. · Trained and knowledgeable in most aspects of the biosciences. · Fully skilled in sales, marketing and most aspects of management related to field operations. · Willingness to travel, work independently, but within a team, to reach common goals and objectives · Management experience in the areas of distributor maintenance and acquisition. Objective Operational management position in the medical / life sciences field working to develop the business potential in the greater Asia-Pacific region. Professional Experience HUMAN BIOCHEMICALS & DIAGNOSTICS, Asia Business Development Manager - Taunusstein, Germany Clinical Laboratory products (clinical chemistry, immunochemistry, coagulation, instrumentation, rapid tests), OEM reagents to the diagnostics industry and over the counter (OTC) products. Charged with distributor acquisition and management, strategic business partnership development, product training or product development for the three different business strategies. 1995 - Present. ROCHE DIAGNOSTIC SYSTEMS, Regional Marketing Manager - Asia, Kuala Lumpur, Malaysia Immunochemistry, Toxicology, Molecular Diagnostics (Polymerase Chain Reaction - PCR) and associated instrumentation. Direct responsibilities are to train customers, distributors, regional Roche personnel, provide technical support, educate and develop the product potential in 9 countries on the Asia-Pacific region. Reporting activity are to three business units, either European, US and the Swiss headquarters point. Measurable success has been directly related to 5 year business and marketing plan development, extensive travel to customer sites, professional medical speakership, product related symposia and trade show organization. Direct reports : 3. 1991 - 1995. ROCHE DIAGNOSTIC SYSTEMS, Immunochemistry Business Unit Marketing Manager, Basle, Switzerland Immunochemistry Instruments and Reagents. Position demanded development of all elements related to product support and introductions on a global basis. Support was internally directed at Roche personnel or distributors to guarantee that sales targets and goals were met to maximize product potential. Direct reports : 7. 1989 - 1991 ABBOTT DIAGNOSTICS DIVISION, Area Strategy Manager - Europe, Middle-East & Africa (EME&A), Wiesbaden, Germany Laboratory Instrumentation and Reagents. Keys to success were formulated strategic plans, pricing, marketing plan development and implementation, as well as promotional efforts throughout EME&A. Position required extensive travel to the Abbott European affiliates to support and conceive local marketing plans and activities - based upon local requirements - and in-line with overall corporate goals and objectives. 1986 - 1989. Previous experience in In-Vitro and In-Vivo (radio-pharmaceutical) diagnostics - DuPont / New England Nuclear - Dreieich, Germany, European Product Manager, 1980 - 1985. Education American University, Washington, DC MBA Candidate Economics/Statistics Widener University, Chester, Pa, - Marketing/Business Management St. Joseph’s University, Phil, PA - B SC Bio-Chemistry Personal Working knowledge of most Microsoft Windows 95 applications (Word, Excel, Powerpoint), IBM (OS2 Internet Connections - Gopher, WWW, email) and Harvard Graphics computer applications related to business management. Have been trained in professional selling skills, marketing and financial management. American citizenship, married, fluent spoken German. References Excellent international professional and personal references can be supplied upon request. World Wide Web http://conquest-prod.iserver.com/jobnetwork/resumesubmit/ messages/1379.html John J. Macey Pfahlgrabenstrasse 17 D-65110, IDSTEIN Germany From owner-diagnostics@net.bio.net Mon Jul 08 23:00:00 1996 Path: biosci!rutgers!sgigate.sgi.com!nntp.coast.net!news-res.gsl.net!news.gsl.net!news.mathworks.com!newsfeed.internetmci.com!news.compuserve.com!news.production.compuserve.com!news From: Mark A. <105006.2541@CompuServe.COM> Newsgroups: bionet.diagnostics,bionet.microbiology,sci.med,sci.med.laboratory,sci.med.pathology Subject: MRSA / VRE Mutation Date: 9 Jul 1996 04:51:22 GMT Organization: Concerned M.T. Lines: 6 Message-ID: <4rsogb$37v$1@mhade.production.compuserve.com> Xref: biosci bionet.diagnostics:958 bionet.microbiology:6540 sci.med:130480 sci.med.laboratory:1690 sci.med.pathology:3120 Concern: any info MRSA / VRE combination / mutation producing Vanco-resistant S. aureus Any info, reference, experience, statistics welcome. Many Thanks!! From owner-diagnostics@net.bio.net Mon Jul 08 23:00:00 1996 Path: biosci!rutgers!uwm.edu!vixen.cso.uiuc.edu!howland.reston.ans.net!nntp.coast.net!news-res.gsl.net!news.gsl.net!portc01.blue.aol.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: rmeader726@aol.com (RMeader726) Newsgroups: bionet.diagnostics Subject: DiagnosisPro web page Date: 8 Jul 1996 22:38:02 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 6 Sender: root@newsbf02.news.aol.com Message-ID: <4rsgma$4rb@newsbf02.news.aol.com> Reply-To: rmeader726@aol.com (RMeader726) NNTP-Posting-Host: newsbf02.mail.aol.com FYI DiagnosisPro medical clinical software web page has just been updated. Come visit : http://home.aol.com/RMeader726 Charles Meader, MD From owner-diagnostics@net.bio.net Mon Jul 08 23:00:00 1996 Path: biosci!rutgers!sgigate.sgi.com!news.msfc.nasa.gov!newsfeed.internetmci.com!bull.hkstar.net!b1!alo From: alo@b1.hkstar.com (Lo Wing Ip Anthony) Newsgroups: bionet.diagnostics Subject: Urine steroid profile Date: 9 Jul 1996 01:50:26 GMT Organization: Hong Kong Star Internet Ltd. Lines: 14 Message-ID: <4rsdt2$469@bull.hkstar.net> NNTP-Posting-Host: b1.hkstar.com X-Newsreader: TIN [version 1.2 PL2] Dear collegues, It would be grateful if anyone could advice on any reference laboratory that will perform a urine steroid profile for the working up of a few cases of male intersex. Thanks. -- Dr. Anthony W.I. Lo (MB ChB, B Med Sc) Tel: (852)-2990-1870 Medical Officer Fax: (852)-2370-0969 Chemical Pathology, Dept. of Pathology Pager: (852)-7205-4096 Princess Margaret Hospital email: anthony-lo@cuhk.hk Lai King Hill, Kowloon. Hong Kong. http://www.hkstar.com/~alo From owner-diagnostics@net.bio.net Mon Jul 08 23:00:00 1996 Path: biosci!rutgers!uwm.edu!lll-winken.llnl.gov!nntp.coast.net!news-res.gsl.net!news.gsl.net!EU.net!sun4nl!Inter.NL.net!usenet From: Remco.van.es@inter.nl.net Newsgroups: bionet.diagnostics Subject: trends in diagnostics Date: Tue, 09 Jul 1996 17:21:06 GMT Organization: Inter.NL.net, The Internet Provider in The Netherlands. Lines: 7 Message-ID: <4ru3ll$nm5@grootstal.nijmegen.inter.nl.net> NNTP-Posting-Host: zd99-23.zaandam.nl.net X-Newsreader: Forte Free Agent 1.0.82 I am interested in current reports or surveys on novel trends in diagnostics(human, veterinairy or food and feed) especiailly on ways of detecting small analytes(antibiotics, drugs etc.) Can anyone give me advise on how to obtain such info? Thanks From owner-diagnostics@net.bio.net Tue Jul 09 23:00:00 1996 Path: biosci!rutgers!uwm.edu!lll-winken.llnl.gov!nntp.coast.net!news.sprintlink.net!news-stk-200.sprintlink.net!news.sprintlink.net!news-pen-14.sprintlink.net!news.sprintlink.net!new-news.sprintlink.net!paperboy.ids.net!usenet From: rand777@ids.net (Robert Randolph) Newsgroups: bionet.diagnostics Subject: Dehydrated Culture Media Sale Date: Wed, 10 Jul 1996 11:36:17 GMT Organization: Randolph Biomedical Lines: 25 Message-ID: <4s08vn$1b4@paperboy.ids.net> Reply-To: rand777@ids.net (Robert Randolph) NNTP-Posting-Host: dyn019a.nwp-ri.ids.net X-Newsreader: Forte Agent .99b.113 Randoloph Biomedical, a speciality manufacturer for microbiology, is offering over a hundred different media for $18 per 500gm / pound bottles. Example: Mycology Agar - List Price $ 72.00 - Sale Price: $18.00 Heart Infusion Agar - List Price $ 84.00 - Sale Price: 18.00 MacConkey w/ MUG - List Price $ 164.00 - Sale Price: 18.00 and lots more..... For complete list go to : http://www2.ids.net/~rand777/media.htm Thank you. -- Robert Randolph Randolph Biomedical 21 McElroy Street West Warwick, RI 02893 401-826-1407 rand777@ids.net http://www2.ids.net/~rand777/home.htm From owner-diagnostics@net.bio.net Wed Jul 10 23:00:00 1996 Path: biosci!daresbury!bioftp.unibas.ch!infobiogen.fr!jussieu.fr!esiee.fr!sgigate.sgi.com!nntp.coast.net!howland.reston.ans.net!news-e2a.gnn.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: ernstphleb@aol.com (Ernstphleb) Newsgroups: bionet.diagnostics Subject: Re: MRSA / VRE Mutation Date: 11 Jul 1996 00:50:57 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 2 Sender: root@newsbf02.news.aol.com Message-ID: <4s217h$et9@newsbf02.news.aol.com> References: <4rsogb$37v$1@mhade.production.compuserve.com> NNTP-Posting-Host: newsbf02.mail.aol.com X-Newsreader: AOL Offline Reader There is an interesting article in last month's June '96) issue of MLO about this topic. Very informative. Very scary. From owner-diagnostics@net.bio.net Wed Jul 10 23:00:00 1996 Path: biosci!G23.RELCOM.RU!9733.g23 From: 9733.g23@G23.RELCOM.RU (Leonid DUDNIKOV) Newsgroups: bionet.diagnostics Subject: Mab's to canine disease Date: 11 Jul 1996 15:16:02 -0700 Organization: SJC "NARVAC", Institute of Virology, Moscow, RUSSIA Lines: 3 Sender: daemon@net.bio.net Distribution: world Message-ID: <31E57D33.7A0A@g23.relcom.ru> NNTP-Posting-Host: net.bio.net We have Mab's to Canine Distemper Virus, Canine Adeno Virus, Canine Parvo Virus. Redy to discation. leonvet@narvac.msk.ru From owner-diagnostics@net.bio.net Wed Jul 10 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!swrinde!newsfeed.internetmci.com!hunter.premier.net!uunet!in1.uu.net!csnews!coopnews.coop.net!boulder.earthnet.net!usenet From: "Phillip E. Schwartz" Newsgroups: bionet.diagnostics Subject: New FDA Regs/Antibodies Date: Thu, 11 Jul 1996 12:39:47 -0700 Organization: Affinity BioReagents, Inc. Lines: 42 Message-ID: <31E55883.3DE2@bioreagents.com> NNTP-Posting-Host: slip12.earthnet.net Mime-Version: 1.0 Content-Type: text/plain; charset=iso-8859-1 Content-Transfer-Encoding: 8bit X-Mailer: Mozilla 2.0 (Win16; I) Please help! Will the individual at your organization who is in charge of regulatory affairs or who is concerned about the negative effects new FDA regulations may have on basic scientific and medical research in addition to health care in general please contact me regarding this matter. I am trying to get as many people to comment on and become involved in a grass-roots effort to keep the FDA from including all antibody research reagents as ‘in vitro diagnostic devices’. Granted, some are but most are not. Please review the information at: http:/www.earthnet.net/~affinity/fda/ It would be optimal if this website could be hotlinked to yours to gain the maximum amount of exposure prior to August 30, 1996 public comment deadline. I would appreciate any comments, questions, referred contacts, etc. that may be useful in changing the language of this pending FDA regulation. FDA Regulation: The Immunohistochemistry Reagents and Kits Regulation: 21/CFR 864 Docket Number: 94P-0342 Sincerely, Phillip E. Schwartz Antibody Partnership Project Manager Affinity BioReagents, Inc. 14818 W. 6th Ave., Suite 13A Golden, CO 80401 TEL: 800-527-4535 FAX: 303-278-2424 email: schwartz@bioreagents.com website: http://www.bioreagents.com/affinity From owner-diagnostics@net.bio.net Thu Jul 11 23:00:00 1996 From: jjmacey@msn.com (john macey) Subject: Asia Biotech / Biomedical Manager Date: 12 Jul 96 05:52:29 -0700 Message-ID: <00005ae5+000001f0@msn.com> Path: biosci!rutgers!sgigate.sgi.com!news.msfc.nasa.gov!newsfeed.internetmci.com!news.sprintlink.net!new-news.sprintlink.net!news.msn.com!msn.com Newsgroups: bionet.diagnostics Organization: The Microsoft Network (msn.com) Lines: 128 Dear Employment Executive, I am presently searching for an operational management position in the life science field dealing in either the capital equipment or biotech / biomedical areas based in the Asia-Pacific region, preferably in either Singapore or Kuala Lumpur, Malaysia. In terms of career accomplishments I have the following to offer: · Progressive up-todate track record in the fields of immunology, toxicology, molecular biology, laboratory instrumentation and reagents and medical technologies. · Proven sales and marketing management success at some of the major players in the medical industry in positions of high visibility. · Ability to adapt to any international business development environment. · Extensive experience with capital equipment. More importantly I can bring the following career experiences: · Knowledge of the Asia market in terms of trends, channels of distribution and cultural differences. · Trained and knowledgeable in most aspects of the biosciences. · Fully skilled in sales, marketing and most aspects of management related to field operations. · Willingness to travel, work independently, but within a team, to reach common goals and objectives · Management experience in the areas of distributor maintenance and acquisition. Objective Operational management position in the medical / life sciences field working to develop the business potential in the greater Asia-Pacific region. Professional Experience HUMAN BIOCHEMICALS & DIAGNOSTICS, Asia Business Development Manager - Taunusstein, Germany Clinical Laboratory products (clinical chemistry, immunochemistry, coagulation, instrumentation, rapid tests), OEM reagents to the diagnostics industry and over the counter (OTC) products. Charged with distributor acquisition and management, strategic business partnership development, product training or product development for the three different business strategies. 1995 - Present. ROCHE DIAGNOSTIC SYSTEMS, Regional Marketing Manager - Asia, Kuala Lumpur, Malaysia Immunochemistry, Toxicology, Molecular Diagnostics (Polymerase Chain Reaction - PCR) and associated instrumentation. Direct responsibilities are to train customers, distributors, regional Roche personnel, provide technical support, educate and develop the product potential in 9 countries on the Asia-Pacific region. Reporting activity are to three business units, either European, US and the Swiss headquarters point. Measurable success has been directly related to 5 year business and marketing plan development, extensive travel to customer sites, professional medical speakership, product related symposia and trade show organization. Direct reports : 3. 1991 - 1995. ROCHE DIAGNOSTIC SYSTEMS, Immunochemistry Business Unit Marketing Manager, Basle, Switzerland Immunochemistry Instruments and Reagents. Position demanded development of all elements related to product support and introductions on a global basis. Support was internally directed at Roche personnel or distributors to guarantee that sales targets and goals were met to maximize product potential. Direct reports : 7. 1989 - 1991 ABBOTT DIAGNOSTICS DIVISION, Area Strategy Manager - Europe, Middle-East & Africa (EME&A), Wiesbaden, Germany Laboratory Instrumentation and Reagents. Keys to success were formulated strategic plans, pricing, marketing plan development and implementation, as well as promotional efforts throughout EME&A. Position required extensive travel to the Abbott European affiliates to support and conceive local marketing plans and activities - based upon local requirements - and in-line with overall corporate goals and objectives. 1986 - 1989. Previous experience in In-Vitro and In-Vivo (radio-pharmaceutical) diagnostics - DuPont / New England Nuclear - Dreieich, Germany, European Product Manager, 1980 - 1985. Education American University, Washington, DC MBA Candidate Economics/Statistics Widener University, Chester, Pa, - Marketing/Business Management St. Joseph’s University, Phil, PA - B SC Bio-Chemistry Personal Working knowledge of most Microsoft Windows 95 applications (Word, Excel, Powerpoint), IBM (OS2 Internet Connections - Gopher, WWW, email) and Harvard Graphics computer applications related to business management. Have been trained in professional selling skills, marketing and financial management. American citizenship, married, fluent spoken German. References Excellent international professional and personal references can be supplied upon request. World Wide Web http://conquest-prod.iserver.com/jobnetwork/resumesubmit/ messages/1379.html John J. Macey Pfahlgrabenstrasse 17 D-65110, IDSTEIN Germany From owner-diagnostics@net.bio.net Thu Jul 11 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!swrinde!newsfeed.internetmci.com!chi-news.cic.net!news.compuserve.com!hd46-168.compuserve.com!user From: a.dario@ieee.org (Amy Dario) Newsgroups: bionet.diagnostics Subject: TECHNICAL APPLICATIONS SPEAKERS NEEDED Date: 12 Jul 1996 20:08:36 GMT Organization: ECM Lines: 28 Message-ID: Reply-To: a.dario@ieee.org NNTP-Posting-Host: hd46-168.compuserve.com Keywords: medical, medical electronics, medical technology, medical engineering, manufacturing, engineering, production, biomedical, biomedical technology, biomedical electronics, biomedical engineering, medical imaging, medical design, design engineering, rapid product development, medical device, medical applications, medical instrumentation, design engineering, engineer, space medicine TECHNICAL APPLICATIONS SPEAKERS NEEDED..... For Northcon/96, an IEEE technology conference/tradeshow, Seattle, Washington, November 4-6. This year the thrust of the technical applications conference is on Medical Electronics. We are looking for technical speakers who are able to speak and/or organize a session on a new, upcoming, or existing technology or technical application especially as it applies in the Medical Electronics field. Other tracks include: Design, Test & Manufacturing and Communications. All papers accepted, will be published in the Northcon Conference Proceedings and distributed world-wide through the IEEE distribution network; as well as receive heavy regional publicity. In the U.S. should you have any questions please feel free to contact me direct via phone at (800) 877-2668, ext. 250 or, all may contact me direct via email. Amy a.dario@ieee.org -- A. Dario, ECM (800) 877-2668, ext. 250 (in the U.S.) a.dario@ieee.org From owner-diagnostics@net.bio.net Fri Jul 12 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!howland.reston.ans.net!news-e2a.gnn.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: rmeader726@aol.com (RMeader726) Newsgroups: bionet.diagnostics Subject: FREEBE DiagnosisPro medical software Date: 12 Jul 1996 22:13:29 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 31 Sender: root@newsbf02.news.aol.com Message-ID: <4s70o9$c9g@newsbf02.news.aol.com> Reply-To: rmeader726@aol.com (RMeader726) NNTP-Posting-Host: newsbf02.mail.aol.com Medical Students/Interns/Residents/Nursing and Physician Asssistant Trainees/Students: Five FREEBE DiagnosisPro medical clinical software packs will be distributed in September ( chosen from the total list of responders). Drawing will be RANDOM. This will likely repeat each three month interval over the next year. So, get on Dr Meader's mailing list !! There are NO strings and results will be published. Also we will be donating five more in August to medical schools anywhere in the world. Notify us if you want your medical center put on THAT list also for random drawing. This software costs $495 ($795 for institutions) and is donated by and made possible as a promotional effort by MedTech USA Inc of Los Angeles, CA . DiagnosisPro (expanded renamed Remind4) has been sold exclusively by them since January 1996 . Charles Meader, MD (Co-author DiagnosisPro) 'CMeader@mv.mv.com' http:home.aol.com/RMeader726 P.S. If you were on previous Remind4 mailing/drawing lists you MUST re-contact us to get on this drawing.. From owner-diagnostics@net.bio.net Sat Jul 13 23:00:00 1996 Path: biosci!ihnp4.ucsd.edu!munnari.OZ.AU!harbinger.cc.monash.edu.au!nntp.coast.net!news-res.gsl.net!news.gsl.net!swrinde!newsfeed.internetmci.com!sgigate.sgi.com!newsfeeder.sdsu.edu!news.iag.net!newsboy.utelfla.com!news.pig.net!news From: sisrael@praxis.net (La) Newsgroups: bionet.diagnostics Subject: Want to Know More about Medical Lab Technology Career Date: 14 Jul 1996 00:13:22 GMT Organization: Praxis Information Group Lines: 11 Message-ID: <4s9e32$o4g@news.pig.net> NNTP-Posting-Host: ptp10.pig.net Mime-Version: 1.0 Content-Type: Text/Plain; charset=US-ASCII X-Newsreader: WinVN 0.99.7 I would like to hear from people who work as medical laboratory technologists. I'd like to know if they like their jobs and what they like best about them or if they're burning out and wish they had trained in something else. I'm considering training in this field and would like to know more about it. Sheila Sisrael@pig.net From owner-diagnostics@net.bio.net Sat Jul 13 23:00:00 1996 Path: biosci!ihnp4.ucsd.edu!munnari.OZ.AU!harbinger.cc.monash.edu.au!nntp.coast.net!news.sprintlink.net!news-stk-200.sprintlink.net!news.sprintlink.net!news-stk-11.sprintlink.net!news.sprintlink.net!news-stk-3.sprintlink.net!news.sprintlink.net!news-fw-22.sprintlink.net!news.sprintlink.net!news-ana-7.sprintlink.net!alpha.sky.net!news From: Technogoddess Newsgroups: bionet.diagnostics Subject: Re: Want to Know More about Medical Lab Technology Career Date: Sat, 13 Jul 1996 22:54:38 -0500 Organization: Laboratory Technology Resources Lines: 32 Message-ID: <31E86F7E.3E0@sky.net> References: <4s9e32$o4g@news.pig.net> Reply-To: gsprague@sky.net NNTP-Posting-Host: ip188.sky.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 2.02 (Macintosh; I; PPC) La wrote: > > I would like to hear from people who work as medical laboratory > technologists. I'd like to know if they like their jobs and what they > like best about them or if they're burning out and wish they had > trained in something else. > > I'm considering training in this field and would like to know more > about it. > > Sheila > Sisrael@pig.net Hi Sheila, I'm not so sure I'm a good person to answer your question right now since my Clinical Laboratory Scientist (Med Tech) career is in flux at the moment. I'd be glad to chat with you via EMAIL for further information. You might also want to post in the newsgroup sci.med.laboratory, I bet you will get a lot of responses there since it is basically a group for lab people. Good Luck! Gwen -- ++++++++++++++++++++++++++++++++++++ Gwen E. Sprague, CLS(NCA), CPC Laboratory Technology Resources "Offering ideas to help your laboratory work smarter not harder" ++++++++++++++++++++++++++++++++++++ From owner-diagnostics@net.bio.net Sun Jul 14 23:00:00 1996 Path: biosci!sasa.gov.uk!odonnell From: odonnell@sasa.gov.uk ("Kevin O'Donnell") Newsgroups: bionet.diagnostics Subject: Moderation Date: 15 Jul 1996 03:13:32 -0700 Organization: Scottish Agricultural Science Agency Lines: 16 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607151112.aa05359@jura.sasa.gov.uk> Reply-To: odonnell@sasa.gov.uk NNTP-Posting-Host: net.bio.net Apologies for the delay in moving to a moderated newsgroup. The reasons are nothing to do with biosci but with uunet itself. When you think about it, it is actually quite a big job, since every news server in the world which carries bionet.diagnostics will have to be modified so that posts are sent to the moderators rather than propagated straight away. The person who deals with conversion of newsgroups to moderated ones is now on holiday, so we will have to wait a couple of weeks more at least. Please simply delete the current slew of unsolicited adverts until then. Kevin Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh From owner-diagnostics@net.bio.net Sun Jul 14 23:00:00 1996 Path: biosci!sasa.gov.uk!odonnell From: odonnell@sasa.gov.uk ("Kevin O'Donnell") Newsgroups: bionet.diagnostics Subject: Taq Patent Latest Date: 15 Jul 1996 05:50:05 -0700 Organization: Scottish Agricultural Science Agency Lines: 23 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607151349.aa08030@jura.sasa.gov.uk> Reply-To: odonnell@sasa.gov.uk NNTP-Posting-Host: net.bio.net As the Roche vs Promega battle rumbles on, here is the latest from Europe (From New Scientist 6 July 1996): "PATENT FAILURE A company (Hoffmann la Roche) hoping to cash in on an enzyme vital for most forms of DNA analysis, including DNA fingerprinting, was last week dealt a blow by the European Patent Office in Munich. The EPO ruled that the enzyme (taq polymerase)cannot be patented because it was first described by scientists in 1976. [snip] The patent office has given the company until 24 october to present further evidence supporting its application." Now can anyone tell me if this means that anyone can sell taq in Europe? Does it mean that scientists are free to produce their own stocks of taq in their own laboratories? Kevin Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh From owner-diagnostics@net.bio.net Sun Jul 14 23:00:00 1996 Path: biosci!rutgers!uwm.edu!news-res.gsl.net!news.gsl.net!news.mathworks.com!newsfeed.internetmci.com!news.compuserve.com!news.production.compuserve.com!news From: Eric Masseus <100577.3707@CompuServe.COM> Newsgroups: bionet.diagnostics,bionet.diagnostics.prenatal,sci.med.immunology,sci.med.laboratory Subject: Reproductive Immunology in Latvia Date: 15 Jul 1996 14:54:41 GMT Organization: Gooi-Noord Hospital, Dept Clin Chem, Netherlands Lines: 4 Message-ID: <4sdm3h$lku$1@mhafn.production.compuserve.com> Xref: biosci bionet.diagnostics:974 bionet.diagnostics.prenatal:172 sci.med.immunology:6958 sci.med.laboratory:1753 An abstract from Evgenia Bikova et al. is available at the abstract page of: http://ourworld.compuserve.com/homepages/Eric_Masseus_eforum From owner-diagnostics@net.bio.net Sun Jul 14 23:00:00 1996 Path: biosci!ihnp4.ucsd.edu!munnari.OZ.AU!harbinger.cc.monash.edu.au!nntp.coast.net!zombie.ncsc.mil!news.mathworks.com!newsfeed.internetmci.com!news.compuserve.com!news.production.compuserve.com!news From: Eric Masseus <100577.3707@CompuServe.COM> Newsgroups: bionet.diagnostics,bionet.diagnostics.prenatal,sci.med.immunology,sci.med.laboratory Subject: Immunotherapy in miscarriage cases Date: 15 Jul 1996 14:57:39 GMT Organization: Gooi-Noord Hospital, Dept Clin Chem, Netherlands Lines: 9 Message-ID: <4sdm93$lku$2@mhafn.production.compuserve.com> Xref: biosci bionet.diagnostics:973 bionet.diagnostics.prenatal:171 sci.med.immunology:6957 sci.med.laboratory:1752 An abstract of Evgenia Bikova et al. can be found at the abstract page of http://ourworld.compuserve.com/homepages/Eric_Masseus_eforum Title: The effective clinical results of immunotherapy in miscarriage cases From owner-diagnostics@net.bio.net Sun Jul 14 23:00:00 1996 Path: biosci!ihnp4.ucsd.edu!munnari.OZ.AU!harbinger.cc.monash.edu.au!nntp.coast.net!dispatch.news.demon.net!demon!user From: filter@firthcom.demon.co.uk (Steve Firth) Newsgroups: bionet.diagnostics Subject: Re: Here is my story Date: Tue, 16 Jul 1996 00:13:13 +0100 Organization: Firth Consulting Lines: 19 Message-ID: References: <4se2n9$fno@netnews.upenn.edu> NNTP-Posting-Host: firthcom.demon.co.uk X-NNTP-Posting-Host: firthcom.demon.co.uk Mime-Version: 1.0 Content-Type: text/plain; charset=iso-8859-1 Content-Transfer-Encoding: 8bit In article <4se2n9$fno@netnews.upenn.edu>, wmh97@aol.com (Bill Hamilton) wrote: >Zamboni here. A word of warning to anyone tempted to reply by mail. This looks like a forgery, the address is given as: >From: wmh97@aol.com (Bill Hamilton) But here's an indication of where it came from: >Organization: University of Pennsylvania >Message-ID: <4se2n9$fno@netnews.upenn.edu> >NNTP-Posting-Host: ts2-55.upenn.edu From owner-diagnostics@net.bio.net Mon Jul 15 23:00:00 1996 Path: biosci!bloom-beacon.mit.edu!spool.mu.edu!uwm.edu!news-res.gsl.net!news.gsl.net!news.mathworks.com!newsfeed.internetmci.com!news.compuserve.com!news.production.compuserve.com!news From: Eric Masseus <100577.3707@CompuServe.COM> Newsgroups: bionet.diagnostics,bionet.diagnostics.prenatal,sci.med.immunology,sci.med.laboratory Subject: immunotherapy in miscarriage cases Date: 16 Jul 1996 06:22:19 GMT Organization: Gooi-Noord Hospital, Dept Clin Chem, Netherlands Lines: 9 Message-ID: <4sfcer$k2t$1@mhadf.production.compuserve.com> Xref: biosci bionet.diagnostics:978 bionet.diagnostics.prenatal:175 sci.med.immunology:6972 sci.med.laboratory:1759 An abstract with the title The effective clinical results of immunotherapy in miscarriage cases of Evgenia Bikova et.al. from Latvia can be found at the abstract page of http://ourworld.compuserve.com/homepages/Eric_Masseus_eforum From owner-diagnostics@net.bio.net Tue Jul 16 23:00:00 1996 From: jjmacey@msn.com (john macey) Subject: Asia Biomedical Manager Date: 17 Jul 96 04:41:18 -0700 Message-ID: <00005ae5+000001f9@msn.com> Path: biosci!rutgers!sgigate.sgi.com!news1.best.com!nntp.primenet.com!news.sprintlink.net!news-stk-3.sprintlink.net!news.sprintlink.net!new-news.sprintlink.net!news.msn.com!msn.com Newsgroups: bionet.diagnostics Organization: The Microsoft Network (msn.com) Lines: 126 Dear Employment Executive, I am presently searching for an operational management position in the life science field dealing in either the capital equipment or biotech / biomedical areas based in the Asia-Pacific region, preferably in either Singapore or Kuala Lumpur, Malaysia. In terms of career accomplishments I have the following to offer: · Progressive up-todate track record in the fields of immunology, toxicology, molecular biology, laboratory instrumentation and reagents and medical technologies. · Proven sales and marketing management success at some of the major players in the medical industry in positions of high visibility. · Ability to adapt to any international business development environment. · Extensive experience with capital equipment. More importantly I can bring the following career experiences: · Knowledge of the Asia market in terms of trends, channels of distribution and cultural differences. · Trained and knowledgeable in most aspects of the biosciences. · Fully skilled in sales, marketing and most aspects of management related to field operations. · Willingness to travel, work independently, but within a team, to reach common goals and objectives · Management experience in the areas of distributor maintenance and acquisition. Objective Operational management position in the medical / life sciences field working to develop the business potential in the greater Asia-Pacific region. Professional Experience HUMAN BIOCHEMICALS & DIAGNOSTICS, Asia Business Development Manager - Taunusstein, Germany Clinical Laboratory products (clinical chemistry, immunochemistry, coagulation, instrumentation, rapid tests), OEM reagents to the diagnostics industry and over the counter (OTC) products. Charged with distributor acquisition and management, strategic business partnership development, product training or product development for the three different business strategies. 1995 - Present. ROCHE DIAGNOSTIC SYSTEMS, Regional Marketing Manager - Asia, Kuala Lumpur, Malaysia Immunochemistry, Toxicology, Molecular Diagnostics (Polymerase Chain Reaction - PCR) and associated instrumentation. Direct responsibilities are to train customers, distributors, regional Roche personnel, provide technical support, educate and develop the product potential in 9 countries on the Asia-Pacific region. Reporting activity are to three business units, either European, US and the Swiss headquarters point. Measurable success has been directly related to 5 year business and marketing plan development, extensive travel to customer sites, professional medical speakership, product related symposia and trade show organization. Direct reports : 3. 1991 - 1995. ROCHE DIAGNOSTIC SYSTEMS, Immunochemistry Business Unit Marketing Manager, Basle, Switzerland Immunochemistry Instruments and Reagents. Position demanded development of all elements related to product support and introductions on a global basis. Support was internally directed at Roche personnel or distributors to guarantee that sales targets and goals were met to maximize product potential. Direct reports : 7. 1989 - 1991 ABBOTT DIAGNOSTICS DIVISION, Area Strategy Manager - Europe, Middle-East & Africa (EME&A), Wiesbaden, Germany Laboratory Instrumentation and Reagents. Keys to success were formulated strategic plans, pricing, marketing plan development and implementation, as well as promotional efforts throughout EME&A. Position required extensive travel to the Abbott European affiliates to support and conceive local marketing plans and activities - based upon local requirements - and in-line with overall corporate goals and objectives. 1986 - 1989. Previous experience in In-Vitro and In-Vivo (radio-pharmaceutical) diagnostics - DuPont / New England Nuclear - Dreieich, Germany, European Product Manager, 1980 - 1985. Education American University, Washington, DC MBA Candidate Economics/Statistics Widener University, Chester, Pa, - Marketing/Business Management St. Joseph’s University, Phil, PA - B SC Bio-Chemistry Personal Working knowledge of most Microsoft Windows 95 applications (Word, Excel, Powerpoint), IBM (OS2 Internet Connections - Gopher, WWW, email) and Harvard Graphics computer applications related to business management. Have been trained in professional selling skills, marketing and financial management. American citizenship, married, fluent spoken German. References Excellent international professional and personal references can be supplied upon request. World Wide Web http://conquest-prod.iserver.com/jobnetwork/resumesubmit/ messages/1379.html John J. Macey Pfahlgrabenstrasse 17 D-65110, IDSTEIN Germany From owner-diagnostics@net.bio.net Tue Jul 16 23:00:00 1996 Path: biosci!daresbury!bioftp.unibas.ch!infobiogen.fr!sansgene.genethon.fr!not-for-mail From: biagioli@sansgene.genethon.fr (Francoise Biagioli) Newsgroups: bionet.diagnostics Subject: Rare Diseases and Orphan Drugs Meeting - September 20,1996 - Paris Date: 17 Jul 1996 17:26:41 +0200 Organization: Genethon -- Human Genome Research Centre Lines: 28 Message-ID: <4sj0nh$980@sansgene.genethon.fr> NNTP-Posting-Host: sansgene.genethon.fr Keywords: Rare diseases On September 20 will be held a meeting on "Rare Diseases and Orphan Drugs" at the Palais du Luxembourg in Paris. The goal of this meeting sponsored by the French Muscular Dystrophy Association (Association Francaise contre les Myopathies,AFM), The Cystic Fibrosis Association (Association Francaise de Lutte contre la Mucovisidose, AFLM), the Ligue contre le Cancer and AIDS is to define the role that patient groups may take in the enactment of the European Orphan Drug Law. That legislation which is being drafted now by the European Union will be based on the American model, the Orphan Drug Act. The Orphan Drug Act is built upon incentives that are aimed at luring pharmaceutical companies into developping drugs that should otherwise have little commercial value. If you believe in the urgency of enacting an Orphan Drug Law in Europe, a representative of your association may want to attend the September 20 meeting. Please contact Dr. Marc BOUILLET at the Association Francaise contre les Myopathies (AFM) : phone : 33-1-42-76-58-58 fax : 33-1-42-76-58-87 Please contact him early as attendance will be limited. If you cannot attend this meeting but wish to help in this effort, please advise Dr. BOUILLET that you would like to be kept informed about the proceedings of the meeting. From owner-diagnostics@net.bio.net Tue Jul 16 23:00:00 1996 Path: biosci!sasa.gov.uk!odonnell From: odonnell@sasa.gov.uk ("Kevin O'Donnell") Newsgroups: bionet.diagnostics Subject: (Fwd) Re: Taq Patent Latest Date: 17 Jul 1996 07:29:34 -0700 Organization: Scottish Agricultural Science Agency Lines: 56 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607171528.aa14302@jura.sasa.gov.uk> Reply-To: odonnell@sasa.gov.uk NNTP-Posting-Host: net.bio.net ------- Forwarded Message Follows ------- To: odonnell@sasa.gov.uk Subject: Re: Taq Patent Latest From: "Jack H. Pincus" Organization: Concentric Network Date: Tue, 16 Jul 96 18:26:02 EST In article <9607151349.aa08030@jura.sasa.gov.uk>, you say... > >As the Roche vs Promega battle rumbles on, here is the latest from >Europe (From New Scientist 6 July 1996): > >"PATENT FAILURE > >A company (Hoffmann la Roche) hoping to cash in on an enzyme vital for most forms of DNA >analysis, including DNA fingerprinting, was last week dealt a blow by >the European Patent Office in Munich. The EPO ruled that the enzyme >(taq polymerase)cannot be patented because it was first described by > scientists in 1976. >[snip] >The patent office has given the company until 24 october to present >further evidence supporting its application." > >Now can anyone tell me if this means that anyone can sell taq in >Europe? Does it mean that scientists are free to produce their own >stocks of taq in their own laboratories? > >Kevin >Dr Kevin O'Donnell "I'm happy, I'm happy >Diagnostics and Molecular Biology and I'll punch the man that says I'm not" >SASA - Ivor Cutler >Edinburgh The EPO is concluding that the patent is not novel because of the publication cited. The patent owner has an opprotunity to rebut that finding and may be able to appeal if the EPO doesn't accept the rebuttal. Whether the patent owner will prevail depends on the contents of the reference cited and whther the patent owner can differntiate their enzyme from the prior art. One would have to compare the reference to the patent application to make that judgement. The process has just started. At this point one cannot predict whether the patent owner or EPO will prevail. Even if the patent owner loses, the first round, they may have a right to appeal, and they may have other patents covering aspects of PCR that would preclude users from practicing the technology without a license. Jack H. Pincus jhpincus@cris.com Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh From owner-diagnostics@net.bio.net Tue Jul 16 23:00:00 1996 Path: biosci!daresbury!bioftp.unibas.ch!infobiogen.fr!sansgene.genethon.fr!not-for-mail From: biagioli@sansgene.genethon.fr (Francoise Biagioli) Newsgroups: bionet.diagnostics Subject: Rare Diseases and Orphan Drugs Meeting - September 20,1996 - Paris Date: 17 Jul 1996 17:27:39 +0200 Organization: Genethon -- Human Genome Research Centre Lines: 27 Message-ID: <4sj0pb$9c6@sansgene.genethon.fr> NNTP-Posting-Host: sansgene.genethon.fr Keywords: rare diseases On September 20 will be held a meeting on "Rare Diseases and Orphan Drugs" at the Palais du Luxembourg in Paris. The goal of this meeting sponsored by the French Muscular Dystrophy Association (Association Francaise contre les Myopathies,AFM), The Cystic Fibrosis Association (Association Francaise de Lutte contre la Mucovisidose, AFLM), the Ligue contre le Cancer and AIDS is to define the role that patient groups may take in the enactment of the European Orphan Drug Law. That legislation which is being drafted now by the European Union will be based on the American model, the Orphan Drug Act. The Orphan Drug Act is built upon incentives that are aimed at luring pharmaceutical companies into developping drugs that should otherwise have little commercial value. If you believe in the urgency of enacting an Orphan Drug Law in Europe, a representative of your association may want to attend the September 20 meeting. Please contact Dr. Marc BOUILLET at the Association Francaise contre les Myopathies (AFM) : phone : 33-1-42-76-58-58 fax : 33-1-42-76-58-87 Please contact him early as attendance will be limited. If you cannot attend this meeting but wish to help in this effort, please advise Dr. BOUILLET that you would like to be kept informed about the proceedings of the meeting. From owner-diagnostics@net.bio.net Wed Jul 17 23:00:00 1996 Path: biosci!rutgers!uwm.edu!homer.alpha.net!news.ultranet.com!usenet From: "Carl M. Good III" Newsgroups: bionet.diagnostics Subject: Syva autosampler Date: Thu, 18 Jul 1996 16:48:18 -0400 Organization: International Technology Partners Lines: 5 Message-ID: <31EEA312.2AF7@ultranet.com> Reply-To: carlg@ultranet.com NNTP-Posting-Host: d17.ltn.ma.ultra.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.0b3 (Win95; I) WE have an old Syva autosampler and need a manual or schematics. Thanks for your help Carl From owner-diagnostics@net.bio.net Fri Jul 19 23:00:00 1996 Path: biosci!bloom-beacon.mit.edu!news.mathworks.com!zombie.ncsc.mil!nntp.coast.net!netnews.worldnet.att.net!newsadm From: rimshot@worldnet.att.net (rimshot) Newsgroups: alt.med.equipment,bionet.diagnostics,sci.chem.analytical Subject: What is this optical component made of?? Date: Sat, 20 Jul 1996 05:28:10 GMT Organization: AT&T WorldNet Services Lines: 17 Message-ID: <4spkd6$khd@mtinsc01-mgt.ops.worldnet.att.net> NNTP-Posting-Host: 248.houston-1.tx.dial-access.att.net X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.diagnostics:984 sci.chem.analytical:4882 Hi, I salvaged some parts (optical & electronic) off a chemistry analyzer that was going to be scraped. The analyzer was a Toshiba medical system. The part in question is the mirror used to relay the light source via fiber-optics to the cuvette with the analyte in it. Another mirror relays the transmittance or absorption of the light source to the detector. The mirror is a small oval inside a clear cube.It is similar to a cube beamsplitter(2 right-angle prisms cemented @ their hypotuse faces), but small -- 10mm x 7mm x13mm. Anyone know what these are made of? Quartz,glass, or plastic? Thanks, rimshot@worldnet.att.net From owner-diagnostics@net.bio.net Sat Jul 20 23:00:00 1996 Path: biosci!agate!howland.reston.ans.net!newsfeed.internetmci.com!newsxfer2.itd.umich.edu!portc01.blue.aol.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: rmeader726@aol.com (RMeader726) Newsgroups: bionet.diagnostics Subject: FREEBE medical/clinical software Date: 20 Jul 1996 20:18:01 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 11 Sender: root@newsbf02.news.aol.com Message-ID: <4srsvp$gc9@newsbf02.news.aol.com> Reply-To: rmeader726@aol.com (RMeader726) NNTP-Posting-Host: newsbf02.mail.aol.com Medical Students, Interns, Residents, Nursing and PA Students: We are giving out five FREEBE DiagnosisPro software packs. Winners will be chosen in September RANDOMLY from our candidate list. Get on the list ... no strings. Charles R. Meader, MD co-author DiagnosisPro medical/clinical software RMeader@aol.com From owner-diagnostics@net.bio.net Sat Jul 20 23:00:00 1996 Path: biosci!agate!newsxfer2.itd.umich.edu!portc01.blue.aol.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: nsebastiao@aol.com (NSebastiao) Newsgroups: bionet.diagnostics Subject: subscribe Date: 21 Jul 1996 00:23:10 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 1 Sender: root@newsbf02.news.aol.com Message-ID: <4ssbbe$m7s@newsbf02.news.aol.com> Reply-To: nsebastiao@aol.com (NSebastiao) NNTP-Posting-Host: newsbf02.mail.aol.com subscribe From owner-diagnostics@net.bio.net Sun Jul 21 23:00:00 1996 Path: biosci!SNEEZY.FHIS.NET!barry From: barry@SNEEZY.FHIS.NET (Barry Schweitzer) Newsgroups: bionet.diagnostics Subject: Information needed on DNA diagnostics Date: 22 Jul 1996 09:39:10 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 23 Sender: daemon@net.bio.net Distribution: world Message-ID: <199607221635.MAA00779@sneezy.fhis.net> NNTP-Posting-Host: net.bio.net Hi There! I would be interested to know whether there are any upcoming meetings that are either focused on or include topics related to DNA diagnostics. Similarly, are there any journals in this area? Finally, does anyone offer special training courses in this area? Thanks in advance for the help! -- Barry Schweitzer, Ph.D. Director Division of Molecular & Structural Biology Walt Disney Memorial Cancer Institute at Florida Hospital 12722 Research Parkway Orlando, FL 32826 Phone: (407) 380-9977 FAX: (407) 380-9978 email: barry@sneezy.fhis.net From owner-diagnostics@net.bio.net Sun Jul 21 23:00:00 1996 Path: biosci!BIOGEN.COM!Tom_Parish/Cambridge/Biogen.BIOGEN From: Tom_Parish/Cambridge/Biogen.BIOGEN@BIOGEN.COM (Tom Parish/Cambridge/Biogen) Newsgroups: bionet.diagnostics Subject: Test for IgG in culture sups Date: 22 Jul 1996 10:40:35 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 13 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607222040.AA9539@cmbexternal.biogen.com> NNTP-Posting-Host: net.bio.net Hi netters, I'm looking for a commerical kit that will quickly quantitate/qualitate murine monoclonal antibody levels in culture supernatants. Sangstat Medical used to sell such a kit but it is no long available. Thanks you in advance. Sincerely, Tom Parish Biogen, Inc. Email Tom_Parish@Biogen.com From owner-diagnostics@net.bio.net Sun Jul 21 23:00:00 1996 Path: biosci!PICASSO.UCSF.EDU!strahan From: strahan@PICASSO.UCSF.EDU Newsgroups: bionet.diagnostics Subject: Re: What is this optical component made of?? Date: 22 Jul 1996 12:21:38 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 69 Sender: daemon@net.bio.net Distribution: world Message-ID: <199607221921.MAA00650@magritte.ucsf.edu> NNTP-Posting-Host: net.bio.net Its easy to tell the difference betweent these substances: Plastic is lightweight, easily scratched, and susceptible to solvent and heat damage.... hence it is highly unlikely that it is made of plastic. Also, plastic only transmits light with wavelengths longer than maybe 500nm. (I've never heard of *serious* optics, like what you describe, being made of plastic... they would need lots of special coatings, and become almost as expensive as the better substances. Glass will transmit shorterwavelenghts of light, but it cuts-off around -400nm, depending on the quality of glass. Quartz cuts off around 210nm, unless it is a Suprasil-type quartz, which is somewhat more expensive but can get down to about 175nm.... by this point, however, the water and oxygen in the atmosphere will be absorbing more than the optics.... so purging with N2 gas is necessary..... And for completeness: for shorter wavelengths, you would probably need CaCl2 or MgCl2 crystals.... these can go down to ~120nm, but they are extremely expensive and fagile. My guess is that your optics are made of a cheap quartz or better quality glass (the distinction is only one of amounts of impurity), as are most optical devices. My reasoning is this: Even though fiberglass can only transmit longer wavelengths, the kind of optics you are describing are worthy of reasonable quality to ensure complete transmition, durability and accurate optical properities. You can test all this with a simple UV-Vis Absorbance spectrometer, or in honor of Archimedes you could even measure the relative density/specific gravity.(I'm sure the CRC Handbook has densities for glass/quartz). More info than you needed, and probably someone else has the actual specs on the machine.... but what the heck! Gary -------------------------------------------------------------------- Gary D. Strahan, Ph.D. Department of Pharmaceutical Chemistry University ov California, San Francisco San Francisco, CA 94143-0446 (415) 476-4378 strahan@picasso.ucsf.edu > From BIOSCI-REQUEST@net.bio.net Fri Jul 19 20:48:24 1996 > > > Hi, > I salvaged some parts (optical & electronic) off a chemistry > analyzer that was going to be scraped. The analyzer was a > Toshiba medical system. > The part in question is the mirror used to relay the light source > via fiber-optics to the cuvette with the analyte in it. Another mirror > relays the transmittance or absorption of the light source to the > detector. The mirror is a small oval inside a clear cube.It is similar > to a cube beamsplitter(2 right-angle prisms cemented @ their hypotuse > faces), but small -- 10mm x 7mm x13mm. > Anyone know what these are made of? Quartz,glass, or plastic? > > > Thanks, rimshot@worldnet.att.net > > > > From owner-diagnostics@net.bio.net Mon Jul 22 23:00:00 1996 Path: biosci!bcm.tmc.edu!news.msfc.nasa.gov!newsfeed.internetmci.com!news.compuserve.com!ix.netcom.com!news From: "Nanci E Donacki" Newsgroups: bionet.diagnostics Subject: Re: Test for IgG in culture sups Date: 23 Jul 1996 00:29:54 GMT Organization: Netcom Lines: 21 Message-ID: <01bb782e$833d9320$9901b8cd@nancied.fast.net> References: <9607222040.AA9539@cmbexternal.biogen.com> NNTP-Posting-Host: vfg-pa4-25.ix.netcom.com X-NETCOM-Date: Mon Jul 22 7:29:54 PM CDT 1996 X-Newsreader: Microsoft Internet News 4.70.1132 Try the Binding Site Mouse RID kit. They have two levels of kits, one for ascites and one for supernatants. Tom Parish/Cambridge/Biogen wrote in article <9607222040.AA9539@cmbexternal.biogen.com>... > Hi netters, > > I'm looking for a commerical kit that will quickly quantitate/qualitate murine > monoclonal antibody levels in culture supernatants. Sangstat Medical used to > sell such a kit but it is no long available. > > Thanks you in advance. > > Sincerely, > > Tom Parish > Biogen, Inc. > Email Tom_Parish@Biogen.com > From owner-diagnostics@net.bio.net Mon Jul 22 23:00:00 1996 Path: biosci!sasa.gov.uk!odonnell From: odonnell@sasa.gov.uk ("Kevin O'Donnell") Newsgroups: bionet.diagnostics Subject: Re: Information needed on DNA diagnostics Date: 23 Jul 1996 03:11:35 -0700 Organization: Scottish Agricultural Science Agency Lines: 32 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607231110.aa21077@jura.sasa.gov.uk> Reply-To: odonnell@sasa.gov.uk NNTP-Posting-Host: net.bio.net On 22 Jul 96 at 9:39, Barry Schweitzer wrote: > Hi There! > > I would be interested to know whether there are any upcoming > meetings that are either focused on or include topics related > to DNA diagnostics. I know of: Advances in Nucleic Acid Amplification and Detection, September 18-19, 1996, Amsterdam, The Netherlands This is a Cambridge Healthtech Institute conference - details from their WWW site at http://www.healthtech.com/conferences/ or email them at chi@healthtech.com They also have a forthcoming conference on genomic target amplification January 7-9, 1997 San Diego, CA Disclaimer: I have no connection with CHI other than having attended one of their conferences. > Similarly, are there any journals in this area? Molecular and Cellular Probes is a pretty good journal in this field. Kevin Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh From owner-diagnostics@net.bio.net Mon Jul 22 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!swrinde!news-res.gsl.net!news.gsl.net!hunter.premier.net!news.cais.net!nntp.primenet.com!news.sprintlink.net!news-stk-3.sprintlink.net!atmnet.net!newshub.cts.com!usenet From: "Bryan Kiehl" Newsgroups: bionet.diagnostics Subject: Thyroid Peroxidase Source Date: 23 Jul 1996 03:55:57 GMT Organization: GenBio Lines: 13 Message-ID: <01bb784b$ebd66fc0$4abfa4c7@home> NNTP-Posting-Host: kiehl.cts.com X-Newsreader: Microsoft Internet News 4.70.1132 -- I am trying to find a source of highly purified thyroid peroxidase to use as a standard for development of a commercial serology kit for thyroid peroxidase. I believe such a source exists in the UK, but cannot seem to locate them. Any help would be appreciated. Thanks. Bryan Kiehl GenBio, San Diego GenBio@msn.com From owner-diagnostics@net.bio.net Mon Jul 22 23:00:00 1996 Path: biosci!aol.com!MHughes77 From: MHughes77@aol.com Newsgroups: bionet.diagnostics Subject: Re: identification rapid tests Date: 23 Jul 1996 16:40:50 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 22 Sender: daemon@net.bio.net Distribution: world Message-ID: <960723193856_368701091@emout15.mail.aol.com> NNTP-Posting-Host: net.bio.net In answer to the following query: >pklease help me to find manifacturers of rapid tests for; mycoplasma >pneumonia IGm, ricketsia thyfi,Q-fever,R. Borunti HCV >antibodiesimmunodots. Rapid tests for several rickettsial diseases, including R. typhi and C. burnetii (Q-fever), are available from Integrated Diagnostics, Inc., located in Baltimore, Maryland, USA (phone 410-737-8500, fax 410-536-1112). Microwell EIA tests for HCV are available from my company (below), and rapid immunodot tests for HCV should become available in a few months. Mark ************************************************ Mark Hughes RapidTest Diagnostics International, Inc. 4524 Felter Road Milpitas, CA 95035 Phone/Fax 501-441-RTDX (441-7839) MHughes77@aol.com ************************************************ From owner-diagnostics@net.bio.net Mon Jul 22 23:00:00 1996 Path: biosci!bcm.tmc.edu!news.msfc.nasa.gov!newsfeed.internetmci.com!howland.reston.ans.net!news-e2a.gnn.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: researchd@aol.com (ResearchD) Newsgroups: bionet.diagnostics Subject: Re: Thyroid Peroxidase Source Date: 23 Jul 1996 16:43:07 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 15 Sender: root@newsbf02.news.aol.com Message-ID: <4t3dgr$s6m@newsbf02.news.aol.com> References: <01bb784b$ebd66fc0$4abfa4c7@home> NNTP-Posting-Host: newsbf02.mail.aol.com X-Newsreader: AOL Offline Reader We can supply both the TPO and the antibodies. Please contact us at phone 201-584-7093, fax 201-584-0210, email:ResearchD@aol.com Or see on line spec sheets on our web site: http://members.aol.com/researchd/index.htm direct page access: antibodies to TPO: htpp://members.aol.com/researchd1/miscabs/index.htm antigen: http://members.aol.com/researchd2/antigens/aglist.htm Sincerely, Bret G Wien Research Diagnostics Inc From owner-diagnostics@net.bio.net Tue Jul 23 23:00:00 1996 Path: biosci!agate!howland.reston.ans.net!ixnews1.ix.netcom.com!ix.netcom.com!ix.netcom.com!netcom.net.uk!news.insnet.net!news.netkonect.net!linux.nildram.co.uk!news From: harbron@nildram.co.uk (Stuart Harbron) Newsgroups: bionet.diagnostics Subject: Re: trends in diagnostics Date: Wed, 24 Jul 1996 06:45:54 GMT Organization: Nildram On-Line Lines: 20 Message-ID: <4t4hcq$hb1@linux.nildram.co.uk> References: <4ru3ll$nm5@grootstal.nijmegen.inter.nl.net> NNTP-Posting-Host: dgt1-ptp29.nildram.co.uk X-Newsreader: Forte Free Agent 1.0.82 Remco.van.es@inter.nl.net wrote: >I am interested in current reports or surveys on novel trends in >diagnostics(human, veterinairy or food and feed) especiailly on ways >of detecting small analytes(antibiotics, drugs etc.) >Can anyone give me advise on how to obtain such info? >Thanks My homepage has some interesting stuff on detecting small *amounts* of material, and there is a NewsLetter too, which this month focusses in on pcr in diagnostics. Not really a survey but it might give you some ideas. Stuart Harbron, PhD The Enzyme Technology Consultancy http://www.nildram.co.uk/~harbron From owner-diagnostics@net.bio.net Tue Jul 23 23:00:00 1996 Path: biosci!bcm.tmc.edu!news.msfc.nasa.gov!newsfeed.internetmci.com!newsxfer2.itd.umich.edu!portc01.blue.aol.com!newstf01.news.aol.com!newsbf02.news.aol.com!not-for-mail From: rmeader726@aol.com (RMeader726) Newsgroups: bionet.diagnostics Subject: FREEBE medical/clinical software DIAGNOSISPRO Date: 23 Jul 1996 20:27:46 -0400 Organization: America Online, Inc. (1-800-827-6364) Lines: 11 Sender: root@newsbf02.news.aol.com Message-ID: <4t3qm2$5hg@newsbf02.news.aol.com> Reply-To: rmeader726@aol.com (RMeader726) NNTP-Posting-Host: newsbf02.mail.aol.com Medical Students, Interns, Residents, Nursing and PA Students: We are giving out five FREEBE DiagnosisPro software packs. Winners will be chosen in September RANDOMLY from our candidate list. Get on the list ... no strings. Charles R. Meader, MD co-author DiagnosisPro medical/clinical software RMeader726@aol.com From owner-diagnostics@net.bio.net Tue Jul 23 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!swrinde!news-res.gsl.net!news.gsl.net!hunter.premier.net!uunet!in3.uu.net!news2.digex.net!access4.digex.net!rschifre From: Richard Schifreen Newsgroups: bionet.diagnostics Subject: Re: Information needed on DNA diagnostics Date: Wed, 24 Jul 1996 13:45:10 -0400 Organization: Express Access Online Communications, USA Lines: 46 Message-ID: References: <199607221635.MAA00779@sneezy.fhis.net> NNTP-Posting-Host: access4.digex.net Mime-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII X-Sender: rschifre@access4.digex.net To: Barry Schweitzer In-Reply-To: <199607221635.MAA00779@sneezy.fhis.net> There is a lot going on in this area. The American Association for Clinical Chemistry (AACC) has a Molecular Division (202)857-0717. Their national meeting is next week in Chicago. The Association of Molecular Pathologists is another good organization (301)571-1880. Their annual meeting is in Baltimore in November. You may also want to check out the San Diego Probes Conference in November sponsored by AACC. AACC has a web-site with a schedule and registration for all of its meetings. Try www.aacc.org. There are a lot of other groups interested in this area, but this should get you started. As far as Training, my employer, Life Technologies, offers a number of training courses in molecular biology techniques. Our web site is www.lifetech.com. Rich Schifreen Life Technologies rschifre@access.digex.net On 22 Jul 1996, Barry Schweitzer wrote: > Hi There! > > I would be interested to know whether there are any upcoming > meetings that are either focused on or include topics related > to DNA diagnostics. Similarly, are there any journals in this > area? Finally, does anyone offer special training courses in > this area? > > Thanks in advance for the help! > > -- > Barry Schweitzer, Ph.D. > Director > Division of Molecular & Structural Biology > Walt Disney Memorial Cancer Institute > at Florida Hospital > 12722 Research Parkway > Orlando, FL 32826 > Phone: (407) 380-9977 > FAX: (407) 380-9978 > email: barry@sneezy.fhis.net > > > > From owner-diagnostics@net.bio.net Tue Jul 23 23:00:00 1996 Path: biosci!agate!howland.reston.ans.net!ixnews1.ix.netcom.com!ix.netcom.com!ix.netcom.com!netcom.net.uk!news.insnet.net!news.netkonect.net!linux.nildram.co.uk!news From: harbron@nildram.co.uk (Stuart Harbron) Newsgroups: bionet.diagnostics Subject: July Newsletter - Focus on PCR Date: Wed, 24 Jul 1996 06:46:03 GMT Organization: Nildram On-Line Lines: 11 Message-ID: <4t4hd2$hb8@linux.nildram.co.uk> NNTP-Posting-Host: dgt1-ptp29.nildram.co.uk X-Newsreader: Forte Free Agent 1.0.82 I have just put up this month's NewsLetter...the focus is on PCR in Diagnostics....Happy Reading. http://www.biochem.ucl.ac.uk/~harbron/TETC/Newsletter/body.html Stuart Harbron, PhD The Enzyme Technology Consultancy http://www.nildram.co.uk/~harbron From owner-diagnostics@net.bio.net Tue Jul 23 23:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!howland.reston.ans.net!Germany.EU.net!main.Germany.EU.net!fu-berlin.de!news.th-darmstadt.de!hrz-ws11.hrz.uni-kassel.de!newsserver.rrzn.uni-hannover.de!tubsibr!rzlimes.gbf-braunschweig.de!news From: Bernd Haase Newsgroups: bionet.diagnostics Subject: Antibody Technology and Applications Meeting Date: Tue, 23 Jul 1996 16:38:08 -0700 Organization: National Research Centre for Biotechnology Lines: 154 Message-ID: <31F56260.1F83@gbf-braunschweig.de> NNTP-Posting-Host: zibnt1.gbf-braunschweig.de Mime-Version: 1.0 Content-Type: text/plain; charset=iso-8859-1 Content-Transfer-Encoding: 8bit X-Mailer: Mozilla 2.0 (Win16; I) Announcing: GBF-Symposium on Antibody Technology and Applications in Health and Environment http://transfac.gbf-braunschweig.de/Symposien/Welcom2.html The meeting will be held in Braunschweig, Germany from September 6th-10th, 1996 For further information please contact: antibody-symposium@gbf-braunschweig.de Goals and Scope The goals of the Symposium are to present latest advances in the field of antibody technology with regard to emerging innovative approaches and applications in health and environment. During the first part of the symposium research progress will be presented in the fields of natural immune repertoires, antibody structure and function and recombinant antibody technology including human and humanized antibodies, phage display techniques, combinatorial libraries and bispecific or catalytic antibodies. In the second part, potentials and problems of antibody expression in cell cultures, transgenic animals and plants will be discussed with regard to the antibody application sessions in the third part of the Symposium. The final sessions will analyze the use of antibody for prophylaxis and therapy and in a variety of other fields with emphasis on the environment. Interactions will be encouraged during round-table sessions where potential uses, common difficulties and limitations of antibody technology will be discussed. Additional time for discussions will be available during poster sessions, social activities and informal periods of time in the Hotel Mercure where most of the participants will be accommodated. Younger scientiests will have the opportunity to submit abstracts for short oral presentations of selected posters in the main sessions. Abstract/Poster Deadline: 15.08.1996 Registration Deadline: 30.08.1996 Preliminary Program Friday 6 Sept. Registration-Orientation-Opening Ceremony-Reception 10.00 - 15.00 Arrival and Registration 17.00 - 19.00 Opening of the Symposium at GBF-Braunschweig (National Research Centre for Biotechnology) 19.30 Welcome Reception Saturday 7 Sept. 08.30 - 10.30 Session I : Antibody Structure and Function 08.30 - 09.10 A. Coutinho (France) 09.10 - 09.50 A. McPherson (USA) 09.50 - 10.30 A. Skerra (Germany) 10.30 - 11.00 Coffee 11.00 - 13.00 Session II : Display Technology, Part 1 11.00 - 11.40 P.-A. Nygren (Schweden) 11.40 - 12.20 A. Griffith (UK) 12.20 - 13.00 A. Plückthun (Switzerland) 13.00 - 14.00 Lunch 14.00 - 16.00 Display Technology, Part 2 14.00 - 14.40 A. Bradbury (Italy) 14.40 - 15.20 G. Smith (USA) 15.20 - 16.00 M. Little (Germany) 16.00 - 16.30 Coffee 16.30 - 18.30 Session III : Combinatorial Libraries 16.30 - 17.10 J. Collins (Germany) / R. Sodoyer (France) 17.10 - 17.50 A. Williamson (USA) 17.50 - 18.20 R. Cortese (Italy) 18.20 - 19.00 B.K. Kay (USA) 19.00 Dinner Sunday 8 Sept. 08.30 - 10.30 Session IV : Human and Humanized Antibodies 08.30 - 09.10 N. Lonberg (USA) 09.10 - 09.50 09.50 - 10.30 10.30 - 11.00 Coffee 11.00 - 13.00 Session V : Bispecific and Catalytic Antibodies 11.00 - 11.40 P. Carter (USA) 11.40 - 12.20 G. Gallacher (UK) 12.20 - 13.00 P. Holliger (UK) 13.00 - 14.00 Lunch 14.30 - 18.00 Excursion 19.00 Dinner Monday 9 Sept. 08.30 - 10.30 Session VI : Expression of MAbs and Tag Systems, Part 1 08.30 - 09.10 B. Brizzard (USA) 09.10 - 09.50 B. Haase (Germany) 09.50 - 10.30 A. Depicker (Belgium) 10.30 - 11.00 Coffee 11.00 - 13.00 Expression of MAbs and Tag Systems, Part 2 11.00 - 11.40 H. Meade (USA) 11.40 - 12.20 H. Köhler (USA) 12.20 - 13.00 13.00 - 14.00 Lunch 14.00 - 16.00 Poster Session 16.00 - 16.30 Coffee 16.30 - 18.30 Session VII : Diagnostics and Imaging 16.30 - 17.10 W. Wels (Germany) 17.10 - 17.50 A. Wu (USA) 17.50 - 18.30 R. Miller (USA) 19.00 Dinner Tuesday 10 Sept. 08.30 - 10.30 Session VIII : Prophylaxis and Therapy, Part 1 08.30 - 09.10 S.J. Cryz (Switzerland) 09.10 - 09.50 F. Emmrich (Germany) 09.50 - 10.30 M.M. Bendig (USA) 10.30 - 11.00 Coffee 11.00 - 13.00 Prophylaxis and Therapy, Part 2 11.00 - 11.40 J. Engberg (Denmark) 11.40 - 12.20 H. Lindhofer (Germany) 12.20 - 13.00 J.R. McGhee (USA) 13.00 - 14.00 Lunch 14.00 - 16.00 Session IX : Environmental Applications, Part 1 14.00 - 14.40 B. Harris (UK) 14.40 - 15.20 E. Conway de Macario (USA) 15.20 - 16.00 J. Köhl (Germany) 16.00 - 16.30 Coffee 16.30 - 18.30 Environmental Applications, Part 2 16.30 - 17.10 M. Tesar (Germany) 17.10 - 17.50 P.V. Choudary (USA) 17.50 - 18.30 19.00 Banquett Wednesday 11 Sept. Departure From owner-diagnostics@net.bio.net Thu Jul 25 23:00:00 1996 Path: biosci!rutgers!uwm.edu!spool.mu.edu!news.sgi.com!news.msfc.nasa.gov!newsfeed.internetmci.com!world1.bawave.com!news.clark.net!mr.net!winternet.com!winternet.com!hydassoc From: hydassoc@parka.winternet.com (Fred Hyde) Newsgroups: bionet.diagnostics,bionet.immunology Subject: Monoclonal antibody to Alpha-feto protein available Date: 26 Jul 96 16:43:48 GMT Organization: StarNet Communications, Inc Lines: 17 Message-ID: NNTP-Posting-Host: parka.winternet.com X-Newsreader: NN version 6.5.0 #2 (NOV) Xref: biosci bionet.diagnostics:1002 bionet.immunology:9415 We have completed our experimentation using monoclonal antibody AFP-27, an IgG2 directed against human alpha-fetoprotein. We have a fairly large excess of the MAb which we would like to dispose of. The antibody is still in the culture medium and was produced on an Endotronics/Cellex Accusyst machine. If you are interested in procuring some of the antibody, please send e-mail and I'll send along a detail sheet on the antibody. Please send E-mail to: hydassoc@winternet.com (or) fredhyde@citilink.com Frederick W. Hyde, Ph.D. Hyde and Associates Biotech Consulting St. Paul, MN 55112 USA From owner-diagnostics@net.bio.net Thu Jul 25 23:00:00 1996 From: rybicka@acsu.buffalo.edu (Krystyna Rybicka) Newsgroups: bionet.diagnostics,bionet.parasitology Subject: Cell organelles in glycogen metabolism Followup-To: bionet.diagnostics,bionet.parasitology Date: 26 Jul 1996 18:37:02 GMT Organization: UB Lines: 61 Message-ID: <4tb38e$dbr@prometheus.acsu.buffalo.edu> NNTP-Posting-Host: orichalc.acsu.buffalo.edu NNTP-Posting-User: rybicka Keywords: Organelles, glycogen Path: biosci!bcm.tmc.edu!pendragon!news.msfc.nasa.gov!newsfeed.internetmci.com!newsreader.sprintlink.net!news.sprintlink.net!news-stk-3.sprintlink.net!news.accutek.com!news.unr.edu!news.acsu.buffalo.edu!acsu.buffalo.edu!rybicka Xref: biosci bionet.diagnostics:1003 bionet.parasitology:1662 Neglected cellular organelles. Virtually all animal cells contain organelles called glycosomes which until now have been neglected in cell biology. This author recently published a comprehensive review article entitled "Glycosomes - the organelles of glycogen metabolism", Tissue & Cell 28 (3) 253-265, 1996. The review, based on biochemical and microscopy data, includes a complete history of glycogen research and the current status of knowledge. Biochemical studies on glycogen metabolism demonstrate the existence of a complex enzymatic machinery involved in glycogen synthesis and degradation, which constantly accumulates glycogen and releases glucose. Such types of cellular machineries represent cell organelles and these were already called glycosomes. There is, however, a confusion in the morphological data concerning glycosomes since early electron microscopic research incorrectly identified the protein component of glycosomes as particles of glycogen. This interpretation, accepted in textbooks and diagnostic pathology, needs an urgent revision. The protein component in glycosomes is fixed by osmium, and stained by uranium and lead. Glycogen accumulated in glycosomes is neither fixed per se nor stained by heavy metals. Glycogen can be visualized by special techniques such as histochemistry or negative staining. The differences in size and in the electron density of glycosomal protein stained by uranium and lead (commonly called Ôglycogen particlesÕ) indicates the metabolic state of glycosomes rather then the amount of glycogen. Several data suggest that the large, electron dense particles may appear when phosphorylase is present (or active) in the organelle, whereas the small and poorly contrasted protein particles would imply the activity of glycogen synthase. Furthermore, there is an intimate association between glycosomes and numerous other cellular organelles including the intermediate filaments and the membranes of endoplasmic reticulum. The association may be related to the energy release by glycosomes, as well as to the transport of glycosomes within the cell, similar to the well recognized transport of ribosomes. The understanding of the structure of glycosomes opens a vast field for the application of modern molecular and cellular biology techniques in order to study cellular metabolism of glycosomes and the role of these ubiquitous organelles in the cell. I would be very happy to receive some feedback on the ideas I outlined in my review article and to continue discussion with anyone interested in glycogen research and in the integrated research on the cell. Please, reply via e-mail: rybicka@acsu.buffalo.edu Krystyna Kielan Rybicka From owner-diagnostics@net.bio.net Thu Jul 25 23:00:00 1996 Path: biosci!rutgers!uwm.edu!cs.utexas.edu!swrinde!newsfeed.internetmci.com!ns1.netone.com!news From: MaryBeth Robinson Newsgroups: bionet.diagnostics Subject: Job Offered: chemistry/biology/polymers Date: Fri, 26 Jul 1996 14:05:22 -0600 Lines: 34 Message-ID: <31F92502.3AFA@heatwatch.com> NNTP-Posting-Host: ddx18.heatwatch.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 2.0 (Win95; I) A young, well financed, and rapidly growing immunodiagnostics company in Boulder, CO is seeking to fill a position for a BS/MS level chemist with 1-3 years experience in the preparation, characterization, and application of polymer films as immobilization platforms for the development of novel immunodiagnostic assay systems. The ideal candidate would have knowledge of surface chemistry and surface analytical techniques, as well as biochemistry and/or protein immobilization. This is very much a cross-disciplinary position. Salary is dependent on qualifications and experience. Medical and Dental insurance are provided. The company also represents an entrepreneurial opportunity for the successful candidate, with equity participation a possibility. The company is engaged in the development of a proprietary immunodiagnostic system that has wide applicability to human clinical, veterinary, and public health arenas. The company is the recipient of significant Federal grants and contracts for advanced diagnostic development, and has large corporate partners supporting proprietary assay development. The company also has other profitable product lines. Boulder is a highly attractive, life style oriented, high tech community located in the foothills of the Colorado Rocky Mountains. Research facilities in the area include University of Colorado, NIST, NOAA, NCAR, and numerous biotech corporations. Additionally, the area is in easy reach of facilities in Denver, Fort Collins, and the Boulder-Longmont corridor. Quality of life here is legendary! Qualified applicants should submit resumes and references to: Dr. MaryBeth Robinson DDx, Incorporated 2830 Wilderness Place Boulder, CO 80301 From owner-diagnostics@net.bio.net Sat Jul 27 23:00:00 1996 Path: biosci!agate!spool.mu.edu!uwm.edu!news-res.gsl.net!news.gsl.net!hunter.premier.net!uunet!in3.uu.net!excelsior.flash.net!usenet From: keller@flash.net (Steve Keller) Newsgroups: bionet.biophysics,bionet.diagnostics,bionet.general,bionet.neuroscience,bionet.neuroscience.amyloid Subject: HELP PLEASE!!! Date: 28 Jul 1996 04:06:47 GMT Organization: Flash-Net Internet Service Provider, 888-FLASHNET Lines: 236 Message-ID: <4tep0n$6mu@excelsior.flash.net> NNTP-Posting-Host: dpm1-184.flash.net Mime-Version: 1.0 Content-Type: Text/Plain; charset=ISO-8859-1 X-Newsreader: WinVN 0.99.8 (beta 2) Xref: biosci bionet.biophysics:2180 bionet.diagnostics:1005 bionet.general:22869 bionet.neuroscience:15039 bionet.neuroscience.amyloid:532 Hello- This letter is from an individual to their doctor seeking help for their condition. If anyone has knowledge of this sort of problem we'd like to hear from you. Thanks. SK The letter is as follows- Dr. (XXXXX), This letter is a bit longer than usual (2½ pages) -- but it is very important that you read it right away, before you even put on your white coat and start seeing patients. Since we have reached a point in our relationship where all the stops have been pulled out, I am going to write the most brutally honest, direct letter I've ever typed out to you. It is my nature, as you know, to be polite and reserved. But I think it may tell you more about me if I just say whatever comes to my mind. First things first: I want to wean off Clorazepate (I''ve been having a problem with my abdomen hurting constantly for the past several days, even to the point of keeping me awake; Phrenilin aggravates this after a certain point, and I'm not sure but that even Clorazepate does the same). If you would give me one fill (about 30) of the low-powered kind (3.75 Mg.) of Clorazepate, that should be enough. As you know from my letter yesterday, I failed miserably in a job I tried to take on Friday morning. I have to tell you, frankly, that I wept over that on and off all day... because it's happened so many times before. As I start this letter, it is 2:00 A.M. Saturday morning. I have been trying without success, despite Clorazepate and even a little Phrenilin, to get to sleep for the past 2 hours. I cannot rest; these thoughts are churning through my head and I might as well put them down on paper. I recently wrote a letter to a friend of mine, Craig Smith by name, at the City Christian Fellowship church. Craig is an extremely gifted Christian recording artist -- his music is beautiful and touching -- as well as a very kind-hearted person who deeply loves God. He presently occupies the role of pastor of that inter-non-denominational church (to which many Catholics come, because the people are so kind, love God so much, and have such a cheering and positive outlook. They firmly believe in what the Bible says). I will include here a modified excerpt from that letter about how things proceeded for me after a certain date in 1978: ******************************************************************************* ****************** From that point on... well, it's almost impossible to put into words, but I'll try to get something of it across to you. Think of the worst, most terrifying nightmare you ever had in your life -- one in which the entire atmosphere was so deadly that you were literally scared spitless. Then, imagine waking up in the morning... and instead of the dream-fabric fading away as it normally does, the fear remains completely with you; you are just as terrified while awake as you were while having the nightmare. And the fear doesn't go away. All day, all night, all the next day... and on and on and on. Next, think of the most bummed-out, depressive, miserable day or brief period of time you've ever experienced; a day or two that is so completely wretched that you really wish you would be the victim of a drive-by shooting -- and I'm not exaggerating. This terrible depression, just as the awful fear, does not go away either. On and on, day after day, week after week, month after month. You can barely sleep; you totally lose interest in doing anything whatsoever; you can hardly function at all. Finally, imagine waking up each day with a powerful feeling of physical malaise. Your body feels bad, all over, in a way you can't put into words. You ache; worse, you get attacks of bad abdominal pain alternating with frequent horrible headaches. You've had the same type of headaches and abdominal pain earlier in your life -- but they're worse and more frequent now. In a word, you feel absolutely horrible. Life is just absolutely wretched for you. Naturally, you seek the help of Physicians and even Psychiatrists / Psychologists and Counselors. You even end up going to Treatment Programs. The Medical Doctors run some usual tests but can't find anything specifically wrong; the Psychiatrists prescribe Antidepressant medications which not only don't help, they actually make the problem even worse (Elavil, for a start; this causes even worse bad dreams). The Counselors talk to you and the Treatment Programs try to put you through disciplinary regimens. None of these do any good whatsoever. Try very hard to imagine all of these things afflicting you at once. There are no answers; no insights; and absolutely no relief. Period. In the understatement of the century, this is pretty darned bad. If you're expected to stay on your feet and function, it can hardly get any worse than this. Now... not too long after these things have got hold of you, you suddenly end up unexpectedly, one morning when you're supposed to start a new job, in hospital for a kidney stone. I don't know if you've ever had one of these but it is said there are very few things that compare with the pain they produce. You will be writhing all over the place, groaning, throwing up, because the pain is so unbearable. You can't possibly drive; someone else has to take you there. Then, at the hospital, you are given shots of painkillers -- I.E., Demerol, Morphine, etc. And now, something very like an epiphany occurs. After the administration of the drugs, the pain recedes into the background. But that is not the thing that immediately grips your attention. What does make you literally sit up and take notice is the fact that not only does the physical pain float away, but all the fear, the depression, the misery, the anguish, the physical malaise -- all these drift away too, as if they had never existed. For the very first time in months, you feel just like you did before all the horrors started. From here on I will make the story as brief as possible. Ever since that ordeal in the hospital (August 1978), my life has been a running battle with opiate-type pain medicine -- because it was the only thing that gave me relief from the unbelievable wretchedness I suffered. I've seen photos of myself from that time frame; one can tell by looking at my face that something was seriously wrong with me -- I had this awful expression on my face, as if I were suffering from some unbearable internal pain. I looked so bad that it drove some girl I used to go to school with to start praying for me. I've probably driven my personal physician (whom I've known for 10 years) close to stark raving mad with my incessant requests for pain-type medication [NOTE: This is you, Dr. (XXXXX)]. A lot of times the requests were legitimate enough, as I do get very bad migraine-type headaches and bad attacks of abdominal pain -- but more frequently it was just to relieve the awful depression and physical bad feeling. Whenever you've seen me with the familiar bit-into-a-sour-lemon countenance, you can just about bet that I haven't had any medication of that type recently and am really suffering. ******************************************************************************* ****************** There was more to that letter, but that was the part pertinent to this one. Dr. (XXXXX), do you begin to get the picture? Can you imagine waking up just about every blessed day, having an indescribable but very bad feeling over your entire body and/or aching all over? And it being a literal torment from hell just to get up and do anything at all? And being so miserable and depressed that you just do not give a damn about anything? In all honesty, I would not want you to. I would not want Adolf Hitler, that unbelievably evil and cruel leader of Nazi Germany, to go through this. Everyone wakes up not feeling so good occasionally, but this goes very far beyond that. This, to me, is a cruelty beyond belief. You may have already guessed this -- but I will confirm to you that I have had a death wish for at least the past 13 years. Now, do not misunderstand me on this: I have never -- repeat emphatically -- never, entertained the idea of ending my own earthly existence. The same deep, deep belief in God that keeps me from falling apart completely makes me know, of a certainty, that a human being does not have the option to end his or her life. It is God-given, for some reason; however unfathomable that reason may be. That does not mean that I have not still desired to die very greatly. I tell you the truth: I have craved death as a man stranded on a desert craves water. I have hoped I would die in an accident. I have fantasized about dying in a short-term but fatal illness. Any way at all, as long as it would let me out of this horrid existence. Naturally, nothing even remotely like that has ever happened to me. Once, years ago, a pretty knowledgeable pharmacist informed me that some medical studies had shown that certain people had either a deficiency of, or another problem which caused the interference of the action of, the natural morphines (endorphins and enkephalins) in the body. He said that these people suffered exactly the same sort of things that I had been suffering for so long -- they just felt awful all the time for no apparent reason. At the time I rejected this idea; for some reason it repelled me. I suppose it was because it sounded like a death sentence, like something no one could do anything about and would be ultimately fatal many years down the road. But now... I'll be damned if I don't think that may be just exactly what's wrong with me. Look at the facts: Apparently there is a natural check-and-balance of endorphin flow in the body at most times, which makes people feel normally good and able to function. I feel horrible all the time; I ache, feel terrible otherwise, and am depressed. It's like the endorphins simply aren't there at all, or are somehow prevented from doing their job. Many people are on an exercise kick. They push themselves hard; they can run until they hurt and keep on running, and then they get what's known as the Runner's High. This is because after a certain point of muscular strain their bodies release endorphins, which make them feel ever so much better (and they weren't feeling bad to start with). Do you know what happens when I exercise to the point of aching, shaking all over, and of nearly fainting? NOTHING. Nothing, that is, except the most horrible feeling I've ever had in my life -- the feeling that I'm going to die and wish that I could. It does not make any difference how often this cruel regimen is repeated. It can be prolonged endlessly and it does not help to the slightest degree. I feel horrible all the time and cannot function at all. Apparently my body is either not producing the endorphins, or else they are somehow being prohibited from doing their job. Doctor -- I am absolutely desperate. What am I going to do? Truly, I might as well be dead as go on like this -- it is pointless! I cannot function; I cannot work; I cannot live. This is exactly why I have sought pain pills, etc. so much. In addition to relieving the very real and violent headaches and bad abdominal pain I sometimes get (sometimes together -- now there's a real treat!), these medications mimic what my body is apparently lacking. With them, I don't generally feel drunk or high; I just feel like I did before this whole damned thing started so many, many years ago. I can live. I can work. I can function. Of course, pain medication isn't perfect by a longshot; its effect goes downhill after a time and it can have side effects. And, of course, it can produce physical dependency over a period of time -- though I've learned to be pretty careful about that. But it is absolutely the only thing I have ever found that make me feel like a normal human being again -- like I felt before that turning point in 1978. The most practical thing I've ever found, surprisingly, has been Lomotil. Let me explain about Lomotil. It doesn't really behave exactly like normal pain medicine. Lomotil takes a long time to take effect; it is very slow and gentle about coming on. I just become gradually aware of feeling normal again, the only side effect being that it makes my mouth a little dry. Also, though the effect of Lomotil is much less pronounced than that of pain pills, the effect is prolonged. 4 to 6 Lomotil can make me feel well enough to function for a whole day. Doctor, this is truly the bottom line: If I really can't have even so much as Lomotil or Darvon any more (which is a pretty poor painkiller, not even as effective as plain Codeine), isn't there for heaven's sake something that can be done? The only other alternative I see is for me to be certified completely and permanently disabled, in which case I am certain that I will probably end up dying soon from sheer misery. Is there anything, anything at all, that can stimulate the production of endorphins in the body? I've heard of certain little externally applied electronic boxes that produce carefully regulated electrical shocks that stimulate endorphins. I've even read that acupuncture can cause this. I know you don't have all the answers. I know that some things are beyond you. But you are very intelligent and well-informed. If you can think of anything practical, anything at all, please discuss them with me TODAY. This has to be addressed NOW; it cannot wait! Yours Sincerely and Desperately, Anonomous -- ______________________________________________________________________ &&&& & & &&& & & &&& &&&& & & & & & & & & & Steve Keller &&&& &&& &&& & & &&& &&&& keller@flash.net & & & & & & & & & (214)279-1531 &&&&& & & &&& &&& &&& &&& & & http://www.flash.net/~keller ______________________________________________________________________ From owner-diagnostics@net.bio.net Sun Jul 28 23:00:00 1996 Path: biosci!agate!spool.mu.edu!uwm.edu!cs.utexas.edu!howland.reston.ans.net!EU.net!sun4nl!surfnet.nl!swsbe6.switch.ch!news.belnet.be!news.sri.ucl.ac.be!opperd From: opperd@licr.ucl.ac.be (Fred Opperdoes) Newsgroups: bionet.parasitology,bionet.diagnostics Subject: Cell organelles Date: 29 Jul 1996 08:59:31 GMT Organization: Universite Catholique de Louvain, Louvain-la-Neuve, Belgium Lines: 37 Distribution: world Message-ID: <4thuhj$18a@sci3.sri.ucl.ac.be> NNTP-Posting-Host: indigo.icp.ucl.ac.be Keywords: glycosomes,trypanosomes,glycogen,metabolism X-Newsreader: TIN [version 1.2 PL2] Xref: biosci bionet.parasitology:1668 bionet.diagnostics:1006 Hi there, The article posted by Krystyna Kielan Rybicka on the bionet.parasitology newsgroup on the existence of glycogen containing particles called "glycosomes" in almost all animal is interesting but provokes a large amount of confusion. As you probably all know glycosomes are the membrane surrounded microbody-like organelles of trypanosomatid and bodonid flagellated protists that belong to the order of the Kinetoplastida. This organelle, is unique to the Kinetoplastida. Glycosomes contain the early enzymes of the glycolytic pathway and glycerol metabolism, such as hexokinase, phosphoglucose isomerase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-phosphate dehydrogenase, phosphoglycerate kinase, glycerol kinase and glycerophosphate dehydrogenase. They also contain enzymes involved in such diversed pathways as carbon-dioxide fixation, pyrimidine biosynthesis, ether-lipid biosynthesis and purine salvage. The organelles resemble the peroxisomes of other eukaryotic organisms in that they may contain the enzymes catalase and superoxide dismutase, Futhermore their enzymes are imported into the organelly with the help of at least two different types of import signals, a C-terminal tripeptide (SKL or similar) and a N-terminal signal peptide, that have also been identified for peroxisomal enzymes. As such the glycosomes are bonafide organelles tha have established their name in the parasitological, biochemical, cell biological and molecular biological literature. A simple search of the Medline (1966-now) database using the keyword "glycosom?" reveals 116 articles of which only 5 do not deal with the glycosomes of the trypanosomatidae. Indeed four of them refer to organelles of glycogen metabolism, the first of which appeared in Russian in 1977, followed then by a few others. Almost nothing was published on the subject in the last 15 years. The first paper on trypanosomatid glycosomes also appeared in 1977, but in English in FEBS letters and this has led to numerous more publications on this subject by many different laboratories from all over the world. I suggest that we reserve the name glycosomes for the trypanosomatid organelles and use a different name or description for the glycogen-containing articles of animal cells. Fred R. Opperdoes From owner-diagnostics@net.bio.net Mon Jul 29 23:00:00 1996 Path: biosci!sasa.gov.uk!odonnell From: odonnell@sasa.gov.uk ("Kevin O'Donnell") Newsgroups: bionet.diagnostics Subject: FWD: Dairy Diagnostics Date: 30 Jul 1996 03:51:44 -0700 Organization: Scottish Agricultural Science Agency Lines: 46 Sender: daemon@net.bio.net Distribution: world Message-ID: <9607301151.aa21061@jura.sasa.gov.uk> Reply-To: odonnell@sasa.gov.uk NNTP-Posting-Host: net.bio.net In article , ivanov@wlab.freenet.kiev.ua (Vladimir Ivanov) says: > >To: microbio@net.bio.net > >Subject: Dairy Microbiology/Diagnostics > >To whom who are concerned > >The extended academic research for Ukrainian Dairy Manufacturers >Association is scheduled at 1996-1998 to evaluate the >seasonal,regional,and technological variations in microbiological >safety of such dairy products as raw and fermented milk , sour >milk cream, curd , and cheese. > >The standard microbiological methods of diagnostics and new ones >,including immune-emzyme techniques, will be used and compared in >this research . > >The companies who are producing and distributing the diagnostics >of pathogenic microorganisms for dairy industry are invited to >send the testing samples of their products for using in this >research. Minimal quantity is a lot to carry out one hundred >analisis. The formal protocols and official report of the studies >and testing the diagnostics in ukrainian dairy industry will be >returned during 1997 and 1998 to the companies who sent their >diagnostics. > >The testing can be carried out by agreement between the company >and Institute of EcoBiotechnology,or without it. The dead line for >the signing of formal agreement for the testing of diagnostics / >sertification of diagnostics for ukrainian market is October >7,1996. > >Contact address: > >Dr.Vladimir Ivanov [Attn.:Dairy diagnostics] >Institute of EcoBiotechnology, >Ukrainian Branch/ World Laboratory, >32 Turgenevskaya Str.,Kiev,252054 >Ukraine > >Tel: 380-44-244-4403 >E-mail: ivanov@wlab.freenet.kiev.ua > > From owner-diagnostics@net.bio.net Wed Jul 31 23:00:00 1996 Path: biosci!biosci!not-for-mail From: Fred Opperdoes Newsgroups: bionet.diagnostics Subject: Glycosome conflict Date: 1 Aug 1996 06:28:32 -0700 Organization: Universite Catholique de Louvain, Louvain-la-Neuve, Belgium Lines: 71 Sender: daemon@net.bio.net Approved: odonnell@sasa.gov.uk Distribution: world Message-ID: <4tqbe0$kae@net.bio.net> NNTP-Posting-Host: net.bio.net In reply to Krystina Rybicka's posting: There are several reasons that can be put forward to apply the name glycosome to the trypanosomatid microbodies rather than to the glycogen-protein particles of animal cells. First, there are some important objections to the use of the privileged suffix -some in the case of an enzyme particle, or an enzyme cluster belonging to a metabolic pathway. By now there is ample evidence in the literature of metabolite channelling as the result of interactions between macromolecules, leading to the formation of pathway particles. Actually some researchers consider the cytosol to represent one big aggregate of macromolecules. If they all would receive the suffix -some the entire cell would be loaded with "somes". Therefore, it is my opinion that the suffix -some should represent something more than just a particle. We (Piet Borst and myself) have chosen the name glycosome to indicate that we deal with a true membrane-bounded organelle, as shown by its morphology, its sedimentation behaviour, its equilibrium density in sucrose and percoll gradients and the fact that all enzymes exhibit a high degree of latency. Moreover, the glycosome constitutes a compartment of glycolytic intermediates, which is clearly separated from the cytosol in intact cells, as has been shown by pulse-labelling experiments. Moreover, there is sufficient historical precedence to reserve the suffix -some for membrane-bounded organelles (e.g. lysosomes, peroxisomes, glyoxysomes, hydrogenosomes, microsomes). For a true pathway particle, enzyme aggregate, or enzyme cluster, the term particle or complex is preferred. Second, Krystina Rybicka states that the name glycosome for glycogen-protein particles was already proposed in 1968 by Scott and Still. This is only partly true. Throughout the entire paper Scott and Still use the term particle to describe the behaviour of glycogen particles. Nowhere do they show the association of their glycogen particles with proteins. The name "glycosome" appears only in the very last sentence of their paper and the proposal for such a name is not based on any experimental fact. Moreover, if they would have meant to propose the name of a new organelle, they would have done so in a more conspicuous place. Third, The fact that there was no solid experimental basis to propose such a name as the "glycosome" for glycogen particles, must have been the reason why this name never became accepted in the glycogen world. It took 9 years before Rybicka used the name again. It was then used occasionally between 1977 till 1981, in not more than a few papers. Fourth, In 1977 Opperdoes and Borst published their paper on the trypanosomid glycosome. Rybicka made mention of this fact in her Virchows Archiv's paper in 1979. At that time the debate on the appropriate or inappropriate use of the name glycosome for either organelle should have started. Instead between 1981 and the 1996 not a single original publication on "glycosomes" of glycogen has appeared in the literature, except the recent review paper by Krystina Rybicka that has provoked this discussion. Finally, contrary to "glycosomes" of glycogen, the glycosomes of the Trypanosomatidae are widely accepted. Since 1977 at least 111 papers with the name glycosome in the title and all referring to the trypanosomatid organelle have been published in the international and refereed literature. Glycosomes are being discussed widely in parasitology text books, in review papers and in textbooks on peroxisomes and cell organelles where they are put at the same level as peroxisomes. My conclusion, therefore, is that there is no reason whatsoever to change the name of the trypanosomatid glycosome. If the use of the name glycosome for trypanosomes would have caused confusion amongst glycogen biochemist and cell biologist, its name would have been changed already 19 years ago, simply by mass action. Fred Opperdoes From owner-diagnostics@net.bio.net Wed Jul 31 23:00:00 1996 Path: biosci!biosci!not-for-mail From: Kevin O'Donnell Newsgroups: bionet.diagnostics Subject: SDA Date: 1 Aug 1996 07:47:31 -0700 Organization: Scottish Agricultural Science Agency Lines: 14 Sender: daemon@net.bio.net Approved: odonnell@sasa.gov.uk Distribution: world Message-ID: <4tqg23$1ik@net.bio.net> NNTP-Posting-Host: net.bio.net Is anyone using or developing strand displacement amplification assays? If so would you like to post a summary of the pros and cons ? Thanks in advance Kevin Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh Dr Kevin O'Donnell "I'm happy, I'm happy Diagnostics and Molecular Biology and I'll punch the man that says I'm not" SASA - Ivor Cutler Edinburgh